Category: Blog

HealthEvidenceDigest offers evidence based coverage of FDA approvals, regulatory updates, clinical research, and drug safety communications. Posts focus on the data behind each decision and explain the potential impact on patient care and clinical practice.

Once-Weekly Navepegritide Is Now FDA-Approved for Children With Achondroplasia. Here Is What the APPROACH Trial Data Actually Shows.

📌 The essentials On February 27, 2026, the FDA approved YUVIWEL (navepegritide, Ascendis Pharma) under the Accelerated Approval Program for increasing linear growth in children aged 2 years and older with achondroplasia with open epiphyses. This is the first and only once-weekly treatment for achondroplasia and the only approved therapy that provides continuous systemic CNP exposure over the weekly dosing interval. The clinical basis: The Phase 2b APPROACH randomized controlled trial (NCT05598320) published in JAMA Pediatrics (November 2025) showed annualized growth velocity (AGV) of 5.84 cm/year with navepegritide versus 3.88 cm/year with placebo (p less than 0.0001), a difference of nearly 2 cm/year additional growth. Accelerated approval context: continued approval may be contingent on confirmatory trials verifying long-term clinical benefit. AGV is the accepted surrogate endpoint; long-term height and functional outcomes are the subject of ongoing follow-up. How it compares: the only other approved therapy for achondroplasia is vosoritide (Voxzogo, BioMarin), approved in 2021, which requires daily injection. YUVIWEL is weekly. Neither has been compared head-to-head in a clinical trial. Rare Pediatric Disease Priority Review Voucher granted alongside this approval. Commercial availability: expected early Q2 2026.

Achondroplasia is the most common form of skeletal dysplasia, affecting approximately 1 in 15,000 to 40,000 live births worldwide. It is caused by a gain-of-function mutation in the FGFR3 gene that overactivates a signaling pathway limiting endochondral bone growth. For decades, treatment was supportive, focused on managing the complications of the condition rather than addressing its underlying biology. That began to change in 2021, when the FDA approved the first drug targeting the root cause of achondroplasia. On February 27, 2026, a second drug entered clinical use offering the same mechanistic approach with a meaningful practical difference: once-weekly dosing instead of once-daily.

YUVIWEL (navepegritide) was developed by Ascendis Pharma using their TransCon technology. Its FDA approval under the Accelerated Approval Program makes it the first and only once-weekly treatment for achondroplasia, supported by robust Phase 2b trial data published in JAMA Pediatrics and presented at major pediatric endocrinology meetings.

What Achondroplasia Is and Why It Extends Beyond Height

To understand what navepegritide does, it helps to understand what achondroplasia actually is, because the condition is more than a difference in stature.

Achondroplasia causes characteristic skeletal features including short stature with rhizomelic (proximal limb) shortening, enlarged head circumference with midface hypoplasia, exaggerated lumbar lordosis, and bowed legs. The average adult height in achondroplasia is approximately 4 feet 1 inch (125 cm) in women and 4 feet 4 inches (131 cm) in men. But height is one dimension of the condition’s impact.

Achondroplasia is a multisystem condition. Many affected individuals face:

Spinal cord compression at the foramen magnum, which can cause central apnea and is the leading cause of sudden death in infancy in achondroplasia
Spinal stenosis in adulthood, causing pain, weakness, and neurological symptoms
Obstructive sleep apnea, occurring in a majority of affected children
Recurrent otitis media and associated hearing loss due to midface hypoplasia
Varus deformity (bowing) of the lower extremities affecting mobility and joint health

This multisystem burden is why the pediatric orthopedic and skeletal dysplasia research community frames achondroplasia pharmacotherapy in terms of improving overall skeletal development, not simply maximizing height. The APPROACH trial endpoints reflect this: in addition to AGV, the trial measured tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio, and the Achondroplasia Child Experience Measure for physical functioning.

The Mechanism: CNP and the FGFR3 Pathway

The biology behind navepegritide requires understanding what the FGFR3 mutation actually does and how CNP counteracts it.

In normal bone growth, endochondral ossification converts cartilage to bone at growth plates. This process depends on chondrocyte (cartilage cell) proliferation and differentiation being maintained at the appropriate rate. FGFR3 (fibroblast growth factor receptor 3) normally acts as a brake on this process. In achondroplasia, the gain-of-function FGFR3 mutation overactivates this brake through the MAPK signaling pathway, suppressing chondrocyte proliferation and slowing bone elongation.

C-type natriuretic peptide (CNP) is a naturally occurring peptide that counteracts FGFR3-MAPK signaling. By activating its receptor (NPR-B) in chondrocytes, CNP inhibits the overactivated MAPK pathway, supporting more normal chondrocyte proliferation and therefore more normal bone growth. The therapeutic logic is to restore CNP-mediated inhibition of the overactive FGFR3 pathway.

Navepegritide is a CNP analog prodrug. “Prodrug” means it is administered in an inactive or slowly releasing form that is converted to active CNP in the body over time. Ascendis Pharma’s TransCon technology uses a hydrolytically cleavable linker to attach CNP to an inert carrier. After subcutaneous injection, the linker degrades slowly, releasing active CNP at a controlled, continuous rate over approximately seven days, matching the weekly dosing interval. This sustained release is the key pharmacological advance over vosoritide, which has a short half-life requiring daily injection to maintain therapeutic CNP exposure.

The APPROACH Trial: What the Evidence Shows

Trial design

The APPROACH trial (NCT05598320) was a Phase 2b, randomized, double-blind, placebo-controlled study enrolling 84 children aged 2 to 11 years with achondroplasia across seven countries. Participants were randomized 2:1 to receive navepegritide 100 μg/kg subcutaneously once weekly or placebo for 52 weeks, followed by a single-arm open-label extension (OLE) in which placebo-treated children crossed over to navepegritide.

The primary endpoint was annualized growth velocity (AGV) at week 52. Secondary endpoints included changes in skeletal proportionality measures (tibial-femoral angle, mechanical axis deviation, fibula-to-tibia length ratio) and the Achondroplasia Child Experience Measure for physical functioning.

52-week results

Endpoint	Navepegritide	Placebo	Significance
Annualized growth velocity (AGV)	5.84 cm/year	3.88 cm/year	p less than 0.0001
Difference in AGV (LS mean)	+1.96 cm/year	Reference	Statistically significant
Tibial-femoral angle	Improved	No improvement	Significant
Mechanical axis deviation	Improved	No improvement	Significant
Fibula-to-tibia length ratio	Improved	No improvement	Significant
Physical functioning (ACH-CPM)	Improved	No improvement	Significant
Safety: grade 3 or higher AEs related to drug	None reported	—	Favorable

Source: Savarirayan R et al. JAMA Pediatrics. 2025;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771. PMC12624480.

The nearly 2 cm/year additional AGV over placebo is the headline number. To contextualize it: untreated children with achondroplasia typically grow at rates substantially below age-matched peers without the condition. Adding nearly 2 cm/year of growth velocity, across years of treatment, could translate to several centimeters of additional stature by the end of linear growth, though height is a secondary consideration given the bone proportionality and functional improvements also observed.

The improvements in tibial-femoral angle and mechanical axis deviation are clinically significant beyond their contribution to height. These measurements reflect the degree of lower limb bowing that is common in achondroplasia and contributes to gait abnormalities, knee pain, and long-term joint health. Improving these parameters addresses functional and structural aspects of the condition, not just growth velocity.

The Achondroplasia Child Experience Measure for physical functioning is a validated patient-reported outcome instrument assessing how children experience the physical limitations of achondroplasia in daily activities. Its improvement alongside the growth and skeletal endpoints indicates that the trial captured changes meaningful to the children themselves, not only measurements observable on radiographs.

Two-year data (May 2026 update)

In May 2026, Ascendis presented two-year APPROACH trial data showing pronounced gains specifically in children aged 5 years and older. In this subgroup, navepegritide produced AGV of 5.84 cm/year (observed mean) versus 3.88 cm/year on placebo over the initial 52 weeks, with durable benefit sustained through the open-label extension. The company also presented data from the combination navepegritide plus lonapegsomatropin (once-weekly growth hormone) program, which showed mean AGV of 8.80 cm/year in treatment-naive children and exceeded the 97th-percentile AGV of average-stature children after 52 weeks, though this combination is investigational and not yet approved.

Accelerated Approval: What It Means Here

The FDA granted YUVIWEL approval under the Accelerated Approval Program, which allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit. The surrogate endpoint for YUVIWEL is annualized growth velocity.

Continued approval is contingent on verification of clinical benefit in confirmatory trials. Ascendis is conducting confirmatory long-term studies evaluating final adult height and clinical functional outcomes. This is standard practice for accelerated approvals in rare pediatric diseases and does not mean the drug’s efficacy is uncertain; it means that the FDA has determined the available evidence is sufficient for approval now while longer-term confirmatory data is generated.

YUVIWEL vs. vosoritide (Voxzogo): how they compare Vosoritide (Voxzogo, BioMarin) was the first disease-targeting drug approved for achondroplasia, in August 2021. It is a CNP analog but not a prodrug: it requires daily subcutaneous injection because its active form degrades quickly in the body. Navepegritide is a prodrug using TransCon technology to achieve weekly dosing through sustained release, providing continuous CNP exposure over the dosing interval rather than daily peaks and troughs. Both target the same CNP-FGFR3 pathway. Neither has been directly compared in a head-to-head randomized trial. The evidence for vosoritide’s efficacy comes from the pivotal ACH-003 trial, which showed a difference of 1.57 cm/year in AGV versus placebo. The APPROACH trial showed a 1.96 cm/year difference for navepegritide versus placebo. Cross-trial comparisons are unreliable and should not be used to conclude one drug is superior. The clinically relevant difference for families is dosing schedule: once-weekly versus once-daily injection. For young children, the reduction in injection frequency is a meaningful quality-of-life consideration.

Safety Profile

The safety profile of navepegritide in the APPROACH trial was favorable, with no grade 3 or higher adverse events attributed to the drug. The most common adverse events were consistent with the expected profile of a subcutaneous injection therapy in children:

Injection site reactions (most common, typically mild and transient)
Headache
Fever
Vomiting
Upper respiratory symptoms

No new safety signals were identified in the extended follow-up period. The full prescribing information includes complete safety data and monitoring recommendations.

Regulatory Designations

YUVIWEL received multiple FDA designations supporting its development:

Accelerated Approval
Rare Pediatric Disease designation (and Rare Pediatric Disease Priority Review Voucher granted alongside approval)
Orphan Drug designation
Breakthrough Therapy designation

As discussed in our post on the first gene therapy for genetic deafness, the Rare Pediatric Disease Priority Review Voucher is a transferable incentive granted upon approval of therapies for rare pediatric conditions. It can be used by Ascendis or sold to another pharmaceutical company to accelerate a different drug’s FDA review, and has market value in the hundreds of millions of dollars. The voucher program exists specifically to incentivize development of treatments for conditions affecting small pediatric populations where commercial markets alone would not support development costs.

What This Approval Means for Families

For a child aged 2 to 11 years with achondroplasia and open growth plates, YUVIWEL is now an FDA-approved treatment option. The practical question for most families will be a conversation with a pediatric endocrinologist or geneticist at a center specializing in skeletal dysplasia about whether navepegritide or vosoritide is the right choice for their child’s specific situation.

Key considerations include the child’s current growth trajectory, whether they are already on vosoritide, family preference for injection frequency, and access and insurance coverage. YUVIWEL is expected to be available through commercial channels beginning early Q2 2026.

For families with children being managed at a skeletal dysplasia center, this conversation should be initiated with the treating team. For families who do not have access to specialized skeletal dysplasia care, the Achondroplasia & Hypochondroplasia Alliance, Little People of America, and the National Organization for Rare Disorders (NORD) maintain physician referral resources, patient community networks, and current information on treatment options.

ClinicalTrials.gov lists ongoing navepegritide trials including the adolescent trial (NCT06732895) for ages 12 to 18 and the combination lonapegsomatropin trial, for families interested in investigational options beyond the current approval.

For related coverage of rare pediatric disease FDA approvals, see our posts on the first gene therapy for genetic deafness approved under the Rare Pediatric Disease PRV program and the UX111 gene therapy for Sanfilippo syndrome now under FDA review.

Sources

Ascendis Pharma FDA approval press release: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older. GlobeNewswire. February 27, 2026.

APPROACH trial primary publication: Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatrics. 2025;180(1):18-25. doi:10.1001/jamapediatrics.2025.4771. PMC12624480.

APPROACH trial registration (Phase 2b): NCT05598320. ClinicalTrials.gov.

Two-year APPROACH data (May 2026): New 2-Year Data from Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged 5 Years. GlobeNewswire. May 6, 2026.

Pediatric Endocrine Society clinical review: Navepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics. pedsendo.org. March 2026.

Contemporary Pediatrics approval coverage: FDA Issues Historic Approval for Navepegritide in Achondroplasia. contemporarypediatrics.com. 2026.

Combination therapy data (HCPLive): Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial. hcplive.com. February 2026.

Adolescent trial registration: NCT06732895. ClinicalTrials.gov.

Vosoritide FDA approval: FDA approves vosoritide for achondroplasia. FDA.gov. August 2021.

YUVIWEL prescribing information: YUVIWEL (navepegritide) full prescribing information. accessdata.fda.gov.

Achondroplasia NORD overview: Achondroplasia. NORD.

NIH GARD achondroplasia: Achondroplasia. rarediseases.info.nih.gov.

CNP biology reference: C-type natriuretic peptide and bone growth. PMC3482906.

Endochondral ossification reference: Endochondral Ossification. StatPearls. NCBI.

Accelerated Approval pathway: Accelerated Approval Program. FDA.gov.

Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

Patient resources: Achondroplasia & Hypochondroplasia Alliance | Little People of America | NORD: Achondroplasia | ClinicalTrials.gov: navepegritide

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about treatment for children with achondroplasia should be made in close consultation with a pediatric endocrinologist, geneticist, or specialist in skeletal dysplasia familiar with the child’s individual growth history and clinical circumstances.

April 12, 2026

The FDA Just Added a New Warning to All Carbidopa/Levodopa Parkinson’s Medications. Here Is What It Says and Why It Matters.

⚠️ Key Safety Summary On March 20, 2026, the FDA issued a Drug Safety Communication requiring new warnings on all carbidopa/levodopa-containing medications for Parkinson’s disease, addressing the risk of vitamin B6 (pyridoxine) deficiency and associated seizures. What the FDA found: 14 confirmed cases of seizures linked to vitamin B6 deficiency in patients on carbidopa/levodopa products, including 2 fatalities. All cases involved levodopa doses exceeding 1,000 mg daily. Latency periods ranged from 23 to 132 months, meaning the problem can develop years into treatment. The seizures are clinically distinctive: they do not respond to standard anti-seizure medications but resolve after vitamin B6 supplementation. In 9 of 9 patients who received B6 supplementation, seizures fully resolved. In some cases, progression to status epilepticus was observed before the diagnosis was made. What is now required: healthcare professionals must evaluate baseline vitamin B6 levels before starting treatment, monitor periodically during treatment, and supplement as needed. If you or someone you care for is on a carbidopa/levodopa medication: do not stop the medication without medical guidance. Report new symptoms (seizures, confusion, numbness, tingling) to your prescriber promptly.

Parkinson’s disease affects approximately 1 million Americans and is the second most common neurodegenerative condition in the United States. The cornerstone of pharmacological management is levodopa, which the brain converts to dopamine to compensate for the progressive loss of dopamine-producing neurons. Levodopa is almost always combined with carbidopa, which prevents levodopa from being metabolized in the bloodstream before it reaches the brain, allowing lower and more effective doses.

These medications work well. Many patients take them for years or decades. But a drug safety communication issued by the FDA on March 20, 2026 has established, for the first time with a formal labeling requirement, that the same mechanism that makes carbidopa/levodopa effective is also depleting vitamin B6, and that this depletion can, in some patients, cause seizures that clinicians may not immediately recognize as B6-related.

What the FDA Found: 14 Cases, 2 Deaths, and a Seizure Type That Resists Standard Treatment

The FDA’s safety review identified 14 cases of seizures linked to vitamin B6 deficiency in patients using carbidopa/levodopa products. Thirteen were postmarketing reports submitted to the FDA Adverse Event Reporting System (FAERS) database; one was identified in the medical literature.

Because the FDA notes that its review relied on spontaneous case reports and that similar cases may exist unreported, the 14 confirmed cases likely underestimate the true incidence.

Key characteristics of the 14 cases:

Feature	Detail
Total confirmed cases	14
All cases: levodopa dose	Above 1,000 mg daily in every case
Higher doses (above 1,500 mg)	Associated with shorter time to deficiency development
Latency period (treatment start to seizure onset)	23 to 132 months
Seizure type	Focal onset seizures with secondary generalization; some progressed to status epilepticus
Response to standard anti-seizure medications	Did not respond in the majority of cases
Response to vitamin B6 supplementation	9 of 9 treated patients had complete resolution
Fatalities	2, both with documented low vitamin B6 levels and poorly controlled seizures
Formulations involved	Oral tablets and enteral suspension
Cases involving Stalevo or Vyalev	None confirmed, but biological plausibility supports similar risk

Source: FDA Drug Safety Communication, March 20, 2026.

The status epilepticus finding is the most urgent clinical detail

The FDA communication notes that progression to status epilepticus was observed in some of the reported cases. Status epilepticus is a neurological emergency, defined as a seizure lasting more than five minutes or two or more seizures without full recovery of consciousness between them. It carries significant risk of brain injury and death if not treated rapidly. In the context of this safety communication, the critical clinical implication is that if a patient on carbidopa/levodopa presents with new-onset seizures that do not respond to conventional anti-seizure medications, vitamin B6 deficiency should be in the differential diagnosis immediately, not as a last resort.

The seizure pattern described is consistent with vitamin B6-dependent epilepsy: focal onset seizures with secondary generalization that resist standard anticonvulsants and resolve with pyridoxine. This pattern has a known biochemical mechanism.

The supporting evidence for B6 deficiency in these cases

Beyond the seizures themselves, the FDA review found additional laboratory and clinical evidence of vitamin B6 deficiency in the reviewed cases:

Elevated homocysteine levels in four cases (B6 is required for homocysteine metabolism; deficiency causes it to accumulate)
Microcytic or normocytic anemia in three cases (B6 is required for heme synthesis)
Neuropsychiatric symptoms in four cases

This multi-system evidence of B6 deficiency strengthens the FDA’s conclusion that “there is reasonable evidence of a causal association between drug products containing carbidopa/levodopa and vitamin B6 deficiency-associated seizures.”

Why Carbidopa/Levodopa Depletes Vitamin B6: The Mechanism

Understanding the biochemical basis of this safety signal helps explain both why it is real and why it has been underrecognized.

Vitamin B6 (pyridoxine) is a water-soluble vitamin with a critical role in over 100 enzymatic reactions in the body, particularly in amino acid metabolism and neurotransmitter synthesis. Its active form, pyridoxal-5′-phosphate (PLP), is the biologically active cofactor.

Carbidopa/levodopa depletes B6 through two mechanisms operating simultaneously:

First: The conversion of levodopa to dopamine (and its subsequent metabolism) consumes PLP as a cofactor. At higher levodopa doses, this ongoing metabolic consumption exceeds normal dietary intake and tissue stores.

Second: Carbidopa itself binds to and inactivates pyridoxal phosphate. This is not a side effect unique to therapeutic use. The structural interaction between carbidopa and PLP is well-characterized biochemically, and it was the reason that earlier levodopa formulations without carbidopa actually caused peripheral B6 depletion through a somewhat different pathway.

The combined effect is a functional reduction in available B6 that compounds over time at higher doses. The long latency period (23 to 132 months) reflects this gradual depletion dynamic: it takes time for dietary intake and tissue stores to be overwhelmed.

What Products Are Affected

The new warning requirement applies to all drug products containing carbidopa and levodopa. These include:

Brand name	Components	Formulation
Sinemet, Sinemet CR	Carbidopa/levodopa	Oral tablets (immediate and controlled release)
Rytary	Carbidopa/levodopa	Oral extended-release capsules
Dhivy	Carbidopa/levodopa	Oral tablets
Crexont	Carbidopa/levodopa	Oral extended-release capsules
Duopa	Carbidopa/levodopa	Enteral suspension (continuous infusion)
Stalevo	Carbidopa/levodopa/entacapone	Oral tablets
Vyalev	Foscarbidopa/foslevodopa	Subcutaneous infusion

No confirmed cases of B6-deficiency seizures were found with Stalevo or Vyalev, which the FDA attributes to lower usage patterns, more recent approval dates, and different dosing requirements. However, the FDA explicitly states that biological plausibility supports similar risk across all formulations, noting that vitamin B6 deficiency was observed in the clinical trials for the injectable product. The warning applies to all formulations.

For Patients and Caregivers

Do not stop your medication without speaking to your neurologist or prescriber first

Carbidopa/levodopa is essential for managing Parkinson’s symptoms. Stopping abruptly can cause serious problems including a Parkinson’s crisis (sudden, severe worsening of symptoms), and in rare cases, a potentially life-threatening condition called neuroleptic malignant-like syndrome from abrupt withdrawal. The solution to B6 depletion is monitoring and supplementation, not stopping the medication.

What to watch for and report to your doctor immediately

Contact your prescriber promptly if you experience any of the following:

New or unexplained seizures of any kind
Confusion or worsening cognitive symptoms
Depression that seems different from your baseline
Numbness, tingling, sharp pains, or weakness in the hands, feet, or limbs
Mouth sores, inflammation of the tongue or lips, or skin changes
Persistent fatigue

If a seizure occurs and does not respond to emergency anti-seizure treatment, inform emergency responders and hospital staff that you are taking carbidopa/levodopa and that vitamin B6 deficiency-associated seizures should be considered. The seizures described in the FDA cases did not respond to conventional anticonvulsants but resolved with B6 supplementation.

Ask your provider about monitoring

Based on the new FDA warning, your prescriber should now:

Check your vitamin B6 level before starting or continuing treatment (particularly if you have been on levodopa for a long time or are on high doses)
Recheck B6 levels periodically during treatment
Consider whether vitamin B6 supplementation is appropriate for your situation

Do not self-supplement with high-dose B6 without medical guidance. While standard dietary doses of B6 are safe, high-dose pyridoxine supplementation (above 50 to 100 mg per day for extended periods) carries its own risk of peripheral neuropathy and should be managed by your provider.

Resources for people living with Parkinson’s disease

The Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research both maintain current patient-facing information on Parkinson’s medications, including updates on drug safety communications. The FDA’s safety communication page is updated as new information becomes available.

For Healthcare Professionals

The FDA’s new labeling requirement translates to the following clinical actions:

When	Action
Before starting carbidopa/levodopa	Evaluate baseline vitamin B6 (pyridoxine) and PLP levels
Periodically during treatment	Recheck B6 levels, frequency guided by dose and clinical status
If new symptoms appear	Evaluate B6 levels promptly regardless of time on therapy
If seizures occur	Recognize that B6 deficiency-associated seizures do not respond to standard anticonvulsants; vitamin B6 administration is the treatment
When titrating to doses above 1,000 mg levodopa	Higher vigilance warranted; doses above 1,500 mg levodopa associated with shorter time to deficiency
If adding anti-seizure medications	Be aware that select anticonvulsants can worsen B6 deficiency

The seizure type is distinctive and should be recognized: focal onset with secondary generalization, consistent with pyridoxine-dependent epilepsy, unresponsive to conventional anticonvulsants, and resolving with B6 administration. Elevated homocysteine, microcytic or normocytic anemia, and neuropsychiatric symptoms are supporting laboratory findings that can help confirm the diagnosis when seizures occur in the context of carbidopa/levodopa use.

Reporting Adverse Events

Patients and healthcare professionals should report adverse events related to carbidopa/levodopa products to the FDA MedWatch program online at fda.gov/safety/medwatch or by calling 1-800-332-1088. Reporting contributes to the pharmacovigilance database that identifies safety signals like this one. The FDA’s 14-case dataset almost certainly undercounts the true incidence of this adverse effect; reporting by clinicians who encounter it helps the agency characterize the full scope.

For related coverage of drug safety communications and post-market safety monitoring on Health Evidence Digest, see our post on the Tavneos (avacopan) serious liver injury warning and what it means when the FDA and a manufacturer disagree about risk and our analysis of why the FDA required post-marketing studies for Foundayo after its accelerated approval.

Sources

FDA Drug Safety Communication (primary source): FDA Is Requiring Warning about Vitamin B6 Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopa. March 20, 2026. fda.gov.

FDA DSC PDF: Drug Safety Communication PDF. fda.gov/media/191605.

FAERS reporting system: Questions and Answers: FDA’s Adverse Event Reporting System. fda.gov.

Vitamin B6 (pyridoxine) overview: Vitamin B6: Fact Sheet for Health Professionals. NIH Office of Dietary Supplements.

Homocysteine and B6: Homocysteine. StatPearls. NCBI.

Status epilepticus: Status Epilepticus. StatPearls. NCBI.

Parkinson’s disease overview: Parkinson’s Disease. NINDS.

Levodopa withdrawal syndrome: Neuroleptic Malignant Syndrome and Parkinsonism-Hyperpyrexia. StatPearls. NCBI.

MedWatch reporting: FDA MedWatch. fda.gov/safety/medwatch.

Patient resources: Parkinson’s Foundation | Michael J. Fox Foundation

Disclaimer: Health Evidence Digest provides general information about FDA drug safety communications and health research for educational purposes. This content is not a substitute for professional medical advice. Patients taking carbidopa/levodopa-containing medications should not discontinue treatment without consulting their neurologist or prescribing clinician. Report new symptoms to your healthcare provider.

April 11, 2026

The FDA Rejected Replimune’s RP1 for Melanoma. Here Is Exactly Why, and What Has to Happen Next.

📌 The essentials On April 10, 2026, the FDA issued a Complete Response Letter (CRL) to Replimune for BLA 125827, its application for vusolimogene oderparepvec (RP1, also known as Vusolimogene oderparepvec, brand name RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on prior PD-1-based therapy. The CRL is not a final rejection. It identifies deficiencies Replimune must address before the application can be reconsidered. The FDA’s concerns are entirely evidentiary, not about safety. The core problem: the pivotal evidence came from a single-arm Phase 2 study (RPL-001-16), which the FDA had previously told Replimune was insufficient to support approval. Without a randomized comparator, the agency could not determine whether observed tumor responses were attributable to RP1, to nivolumab, or to patient-specific factors. The path forward: the FDA requires adequate and well-controlled randomized trials demonstrating RP1’s independent contribution to clinical benefit. Replimune may request a Type A meeting with the FDA to discuss whether modifications to the ongoing IGNYTE-3 Phase 3 trial (NCT05765994) could address the requirements.

Unresectable melanoma that has progressed after checkpoint inhibitor therapy is one of the hardest clinical scenarios in oncology. PD-1 inhibitors like pembrolizumab and nivolumab transformed the treatment of metastatic melanoma beginning in 2014, extending survival for patients who previously had very limited options. But when melanoma progresses on those drugs, the question of what comes next has no clear answer. The approved options are limited, the responses are modest, and the disease is often aggressive by the time it reaches that stage.

Vusolimogene oderparepvec (RP1) is an oncolytic herpes simplex virus, an engineered virus designed to selectively infect and kill tumor cells while simultaneously triggering a systemic immune response. It was specifically developed to work in combination with checkpoint inhibitors and showed promising results in early-phase testing. Replimune submitted a Biologics License Application (BLA) based on Phase 2 data in combination with nivolumab.

On April 10, 2026, the FDA responded with a Complete Response Letter. The decision does not close the door on RP1. It identifies, in specific and instructive detail, exactly what the clinical evidence package was missing and what is required to proceed.

What Oncolytic Immunotherapy Is and Why RP1 Is Interesting

To understand what Replimune was trying to do, and why the regulatory challenge is real rather than arbitrary, it helps to understand the mechanism of oncolytic virotherapy.

Oncolytic viruses are engineered to selectively replicate inside tumor cells, causing them to burst and die, while largely sparing normal tissue. The death of those tumor cells releases antigens and danger signals that can alert the immune system to the presence of cancer. In theory, an oncolytic virus can convert a “cold” tumor, one with low immune infiltration and low response to checkpoint inhibitors, into a “hot” one where the immune system actively attacks the cancer.

RP1 is engineered from herpes simplex virus type 1 (HSV-1) with two modifications designed to enhance its therapeutic profile: deletion of the ICP34.5 gene to reduce neurovirulence and enhance tumor selectivity, and insertion of a GALV-GP R(-) fusogenic membrane glycoprotein that causes infected cells to fuse with neighboring cells, amplifying tumor cell death and antigen release. This fusogenic enhancement is what distinguishes RP1 from talimogene laherparepvec (T-VEC, Imlygic), the only previously approved oncolytic virus for melanoma, which does not carry this feature.

RP1 is administered by direct injection into tumor lesions (intratumoral injection). The proposed mechanism of clinical benefit involves both local tumor destruction at injected lesions and systemic immune activation that could, in principle, attack non-injected lesions and metastatic sites. That systemic effect is the central clinical and regulatory question: does injecting a virus into accessible tumors produce meaningful benefit throughout the body, and can a clinical trial reliably detect and attribute that benefit?

What the RPL-001-16 Trial Showed and Why It Was Not Enough

The pivotal evidence for the BLA came from RPL-001-16 (NCT03767348), a Phase 2 single-arm study evaluating RP1 plus nivolumab in patients with advanced cutaneous melanoma. The trial enrolled patients whose disease had progressed on prior PD-1 therapy, exactly the patient population with the highest unmet need in this disease.

In the Phase 2 data, the combination showed an objective response rate that generated initial enthusiasm in the oncology community. However, the FDA’s concern was not primarily about the magnitude of the responses. It was about whether the study design allowed any reliable conclusion about what caused them.

The FDA had communicated to Replimune prior to BLA submission that a single-arm trial in this combination setting was insufficient to demonstrate RP1’s contribution to clinical benefit. Replimune proceeded with the BLA nonetheless, apparently believing the strength of the data could overcome the design limitation.

It could not.

Why the FDA Issued the CRL: Four Specific Problems

1. The study design could not isolate RP1’s contribution

The fundamental problem with a single-arm trial combining RP1 with nivolumab is that nivolumab has established activity in melanoma. When a trial shows responses in patients receiving a known-active drug plus a new drug, with no control arm receiving the known-active drug alone, it is impossible to determine how much of the response came from the new drug. The FDA had been explicit that this design flaw was fatal to the application before it was submitted. A randomized trial comparing RP1 plus nivolumab versus nivolumab alone would allow direct attribution of incremental benefit to RP1.

2. The study population was too heterogeneous

Patients enrolled in RPL-001-16 varied substantially in prior treatments received, disease burden, lesion characteristics, and performance status. This variability made any cross-trial comparison unreliable and prevented meaningful benchmarking against external data. When a study is highly heterogeneous in ways not controlled by randomization, the results reflect the characteristics of who happened to be enrolled as much as the effects of the drug being studied.

3. Response assessments were uncertain and potentially confounded

The FDA identified multiple specific methodological issues that could artificially inflate the observed response rate:

Non-injected lesion problem: Many patients who showed an overall response did not have measurable non-injected target lesions. Since RP1 is injected directly into accessible tumors, any responses in those directly injected lesions could reflect local tumor destruction by the virus rather than systemic immune activation. If the drug’s value lies in producing systemic benefit beyond the injection site, the evidence needs to show response in tumors the drug never touched. In many cases, it could not.

Re-injection timing: Some patients received additional RP1 injections after new or enlarging lesions appeared. Under standard RECIST response criteria, new lesions or tumor enlargement typically counts as progression. Injecting the drug into new lesions and then observing their shrinkage can look like a response while obscuring what is actually a progressive disease pattern.

Surgical excisions and biopsies: Several patients underwent surgical removal or biopsy of lesions during the trial. These procedures can reduce measurable tumor burden in ways that are indistinguishable from drug-induced tumor shrinkage on imaging, inflating apparent response rates.

Local rather than central pathology review: Response assessments were performed by local investigators rather than a blinded central review committee. Local review is more susceptible to unconscious bias and inconsistency in applying response criteria than independent centralized review.

These factors collectively undermined the reliability of the reported objective response rate and duration of response as measures of true drug effect.

4. Supplemental data from the RP1-104 study were insufficient

Replimune attempted to support the BLA with additional data from an ongoing randomized Phase 2/3 study (RP1-104). However, the FDA found that only a small fraction of the planned study population had been treated at the time of submission, the data lacked independent review, the duration of response data were immature, and there was no prespecified statistical plan for the progression-free survival endpoint. The FDA concluded that these early, exploratory findings from RP1-104 could not compensate for the fundamental deficiencies in the pivotal RPL-001-16 study.

What the Field of Oncolytic Immunotherapy Needs to Learn From This

The RP1 CRL is instructive beyond Replimune specifically. It articulates the evidentiary standards the FDA will apply to intratumoral therapies combined with checkpoint inhibitors, and those standards were not invented for this application. They reflect well-established principles of clinical trial design.

Single-arm trials cannot isolate combination drug contributions. When a novel therapy is combined with an agent that already has proven activity in the indication, a randomized trial with an appropriate comparator arm is not optional. This principle applies across oncology, not just to oncolytic viruses.

Intratumoral therapies must demonstrate systemic activity. The clinical value proposition of an oncolytic virus is not that it kills directly injected tumors. Surgery can do that. The value proposition is that it triggers systemic immune responses that benefit the whole patient. Evidence of that systemic benefit requires trial designs that can detect and attribute responses in non-injected disease sites.

Methodological details matter enormously in solid tumor oncology. Re-injection timing, lesion selection for target measurement, the role of concurrent procedures, and the choice of central versus local review are not administrative details. They are scientifically material choices that determine whether a response rate number means what it appears to mean.

The FDA’s prior communications are not suggestions. Replimune knew before submitting its BLA that the agency had reservations about the single-arm design. Proceeding without addressing that concern was a high-risk regulatory strategy that did not succeed. The FDA’s pre-BLA communications and Type B meetings are the appropriate time to reach agreement on whether an evidentiary package is sufficient.

The Path Forward: IGNYTE-3

Replimune has an ongoing Phase 3 trial that may ultimately provide the evidence the FDA requires. The IGNYTE-3 trial (NCT05765994) is a randomized, controlled study designed specifically to address the gap identified in RPL-001-16. The FDA has indicated that Replimune may request a meeting to discuss whether modifications to IGNYTE-3 or additional studies could meet the requirements outlined in the CRL.

What that trial will need to show, based on the CRL’s specific feedback, is a clear, independently reviewed, randomized demonstration that the combination of RP1 plus nivolumab produces greater clinical benefit than nivolumab alone in patients with unresectable advanced melanoma that has progressed on prior PD-1 therapy. The primary endpoint will need to capture systemic activity, not just responses at injected sites, and the trial design will need to prevent the confounding issues that undermined RPL-001-16.

The timeline for such a result is measured in years, not months. Until IGNYTE-3 or another adequate study reports, RP1 remains investigational for this indication.

What This Means for Patients With Advanced Melanoma

For patients with unresectable melanoma that has progressed on PD-1 therapy, RP1 is not currently an approved treatment option. The CRL means it will remain investigational until adequate trial evidence is generated and reviewed.

The approved options for melanoma after progression on PD-1 therapy are limited and depend on individual patient factors including BRAF mutation status, prior treatment history, and performance status. Current options include:

BRAF/MEK inhibitor combinations (dabrafenib plus trametinib, vemurafenib plus cobimetinib, encorafenib plus binimetinib) for patients with BRAF V600 mutations
Ipilimumab (Yervoy) alone or in combination with nivolumab in appropriate patients
Talimogene laherparepvec (T-VEC, Imlygic) for unresectable local or regional disease, the only currently approved oncolytic therapy in melanoma
Clinical trial enrollment

For patients with unresectable advanced melanoma, especially those who have progressed on checkpoint inhibitor therapy, clinical trial enrollment is not a last resort. It is often the best option to access novel therapies in development. The IGNYTE-3 trial may have open enrollment sites. Additional clinical trial options can be searched at ClinicalTrials.gov.

The Melanoma Research Foundation and the Skin Cancer Foundation both maintain current information on melanoma treatment options and clinical trial resources.

For related coverage of how the FDA evaluates clinical evidence and what happens when that evidence is found insufficient, see our post on the camizestrant ODAC vote and what it reveals about ctDNA-guided treatment strategies and our analysis of pembrolizumab becoming the first approved immunotherapy for ovarian cancer to understand what a successful immunotherapy approval requires.

Sources

Complete Response Letter (primary source): CRL BLA125827 April 10, 2026. open.fda.gov.

Replimune press release: Replimune Announces Receipt of Complete Response Letter from FDA for RP1 (Vusolimogene Oderparepvec) BLA. Replimune. April 2026.

IGNYTE-3 Phase 3 trial: NCT05765994. ClinicalTrials.gov.

RPL-001-16 Phase 2 trial: NCT03767348. ClinicalTrials.gov.

Oncolytic virus immunotherapy review: Oncolytic Viruses: A New Class of Immunotherapy Agents. PMC8709598.

T-VEC FDA approval: FDA approves talimogene laherparepvec for melanoma. FDA.gov.

Nivolumab melanoma approval: FDA approves nivolumab for melanoma. FDA.gov.

RECIST criteria: New Response Evaluation Criteria in Solid Tumours (RECIST). PMC3107543.

PD-1 inhibitors overview: Checkpoint Inhibitors. StatPearls. NCBI.

Complete Response Letter explained: Complete Response Letter. FDA.gov.

NCCN melanoma guidelines: Melanoma Cutaneous: Clinical Practice Guidelines. NCCN.

BRAF inhibitors: BRAF Inhibitors. cancer.gov.

Melanoma cancer overview: Advanced Melanoma Treatment. American Cancer Society.

Patient resources: Melanoma Research Foundation | Skin Cancer Foundation | ClinicalTrials.gov: melanoma oncolytic

Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. RP1 (vusolimogene oderparepvec) is not currently FDA-approved for any indication. Treatment decisions for advanced or metastatic melanoma should be made in consultation with a qualified oncologist experienced in melanoma and immunotherapy.

April 10, 2026

The First Oral IL-23 Receptor Blocker for Psoriasis Is FDA-Approved. Here Is What the ICONIC Trial Data Actually Shows.

📌 The essentials On March 18, 2026, the FDA approved ICOTYDE (icotrokinra, Johnson & Johnson) for the treatment of moderate to severe plaque psoriasis in adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. What makes it mechanistically distinctive: icotrokinra is the first oral peptide that directly blocks the IL-23 receptor, not the IL-23 ligand. All currently approved IL-23-targeting biologics (guselkumab, risankizumab, tildrakizumab) are monoclonal antibodies targeting the IL-23 cytokine itself. Icotrokinra works at the receptor level, introducing a distinct pharmacological approach in an established mechanism. How it is taken: one 200 mg tablet once daily, taken with water upon waking, at least 30 minutes before eating. May be dispersed in water for patients who have difficulty swallowing tablets. Who it is approved for: adults and adolescents aged 12 and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. The clinical basis: the Phase 3 ICONIC clinical development program across five randomized controlled trials enrolling more than 2,500 patients. Key efficacy numbers at week 16 across trials: IGA 0/1 (clear or almost clear skin) approximately 65 to 70%; PASI 90 approximately 50 to 57%. In head-to-head comparisons, icotrokinra showed superiority to deucravacitinib (Sotyktu) on both primary endpoints. At 52 weeks, complete skin clearance (PASI 100) rates increased to 48 to 49% in two pivotal studies.

Plaque psoriasis is among the most common immune-mediated skin conditions in the world, affecting more than 125 million people globally. It is not primarily a cosmetic problem. The chronic inflammation that drives the characteristic plaques, scaling, and itch also carries systemic consequences: psoriatic arthritis develops in up to 30% of patients, and individuals with moderate to severe disease have elevated cardiovascular risk, increased rates of depression and anxiety, and substantially reduced quality of life.

The treatment landscape for moderate to severe plaque psoriasis transformed with the arrival of biologics targeting the IL-17 and IL-23 pathways in the 2010s and 2020s. These injectable therapies produce very high rates of skin clearance but require subcutaneous or intravenous administration, carrying an injection burden that affects adherence for some patients. The oral options in this space have been limited: apremilast (Otezla) is a PDE4 inhibitor with more modest efficacy than IL-17 or IL-23 biologics, and deucravacitinib (Sotyktu) targets TYK2 and has shown meaningful but not biologic-comparable clearance rates.

ICOTYDE (icotrokinra), approved March 18, 2026, enters this landscape as the first oral therapy targeting the IL-23 receptor directly. The efficacy data from the ICONIC program puts it in a different category from prior oral options and, on some measures, in range of biologic-level responses, in a once-daily pill.

What Icotrokinra Is and How It Works

IL-23 (interleukin-23) is a cytokine that plays a central role in the inflammatory cascade driving plaque psoriasis. It activates and sustains Th17 cells, the immune cell population that produces IL-17, the downstream cytokine directly responsible for much of the skin inflammation in psoriasis. Blocking IL-23 at any point in this pathway reduces Th17 activation and downstream inflammation.

Existing IL-23-targeting biologics work by binding to the p19 subunit of the IL-23 cytokine itself, preventing it from activating its receptor. Icotrokinra takes a different approach: it is an oral peptide that binds directly to the IL-23 receptor (IL-23R) on the surface of immune cells, blocking the receptor from receiving the IL-23 signal regardless of how much IL-23 is present. This is mechanistically analogous to blocking the lock rather than confiscating the key.

The ability to deliver this level of receptor-targeted precision in an oral small molecule format is what makes icotrokinra mechanistically distinctive. It is not a large protein antibody requiring injection. It is a peptide that survives oral ingestion and reaches the target receptor after absorption from the gastrointestinal tract. The pharmacological challenge of engineering peptides that can do this reliably is substantial, which is why icotrokinra is the first of its kind to reach approval.

How icotrokinra compares to other oral psoriasis treatments Apremilast (Otezla) is an oral PDE4 inhibitor that broadly dampens inflammatory signaling. It produces IGA 0/1 rates of approximately 20 to 30% at 16 weeks and PASI 75 rates of approximately 40% in pivotal trials. It is generally considered a step below biologics in efficacy for moderate to severe disease. Deucravacitinib (Sotyktu) is an oral TYK2 inhibitor that selectively suppresses IL-23 and IL-12 signaling. In its pivotal POETYK PSO-1 and PSO-2 trials, it produced IGA 0/1 rates of 53 to 58% and PASI 75 rates of 58 to 65% at week 24, positioning it meaningfully above apremilast. Icotrokinra produced IGA 0/1 rates of 65 to 70% and PASI 90 rates of 50 to 57% at week 16 across its pivotal trials, with head-to-head superiority demonstrated directly against deucravacitinib in ICONIC-ADVANCE 1 and 2. No head-to-head trial comparing icotrokinra to IL-17 or IL-23 biologics has been completed. Where icotrokinra fits in the treatment hierarchy will be determined by payer formularies, prescriber experience, and individual patient considerations including injection hesitancy, comorbidities, and treatment history.

The ICONIC Clinical Development Program: What the Data Shows

The FDA approval is based on five Phase 3 randomized controlled trials collectively enrolling more than 2,500 patients, designated the ICONIC program. The co-primary endpoints across studies were the proportion of patients achieving IGA 0/1 (clear or almost clear skin) with at least a 2-grade improvement, and PASI 90 (at least 90% improvement in psoriasis severity from baseline), both at week 16.

ICONIC-ADVANCE 1 and 2: the pivotal approval studies with active comparator

The two pivotal trials supporting the approval are ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), published simultaneously in The Lancet in September 2025. These trials were randomized, double-blind, placebo-controlled and active-comparator-controlled, comparing icotrokinra (200 mg once daily) to both placebo and deucravacitinib (6 mg once daily) in adults with moderate to severe plaque psoriasis.

Endpoint at Week 16	Icotrokinra	Placebo	Deucravacitinib
IGA 0/1 (ADVANCE 1)	68% (213/311)	11% (17/156)	49%
IGA 0/1 (ADVANCE 2)	70% (227/322)	9% (7/82)	49%
PASI 90 (ADVANCE 1)	55% (171/311)	4% (6/156)	36%
PASI 90 (ADVANCE 2)	57% (184/322)	1% (1/82)	38%
PASI 100 complete clearance (ADVANCE 1, Week 16)	~33%	Less than 1%	~17%
PASI 100 complete clearance (ADVANCE 2, Week 16)	~33%	Less than 1%	~16%

Source: Gold et al. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.

Both coprimary endpoints and all key secondary endpoints were met in each study. Icotrokinra demonstrated statistically significant superiority over deucravacitinib on both IGA 0/1 and PASI 90 at week 16, with treatment differences of approximately 19 to 20 percentage points on IGA 0/1 and approximately 18 to 19 percentage points on PASI 90 versus deucravacitinib. This head-to-head superiority over the most recently approved oral systemic therapy is the most clinically significant efficacy finding in the dataset.

ICONIC-LEAD: adolescent and adult data

ICONIC-LEAD (NCT06095115) enrolled 684 participants (456 icotrokinra, 228 placebo) in a 2:1 randomization. This study evaluated both adults and adolescents and provides the specific data supporting the pediatric indication. At week 16, 65% of icotrokinra-treated patients achieved IGA 0/1 versus 8% with placebo (difference 56%; 95% CI 50 to 62%), and 50% achieved PASI 90 versus 4% with placebo (difference 45%; 95% CI 40 to 50%). By week 24, these rates improved to 74% IGA 0/1 and 65% PASI 90.

ICONIC-TOTAL: high-impact sites

ICONIC-TOTAL (NCT06095102) specifically enrolled patients with plaque psoriasis affecting high-impact and difficult-to-treat areas including scalp, genitals, and hands/feet. At 52 weeks, 72% of patients with scalp psoriasis achieved scalp-specific IGA 0/1 clearance. Genital and hand/foot clearance rates were similarly high. These difficult-to-treat locations are often where patients report the greatest impact on quality of life and where many existing systemic therapies show lower effectiveness than in non-special site disease.

52-week durability data

One-year data from ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD, presented at the 2026 American Academy of Dermatology Annual Meeting in March 2026, showed that response rates continued to improve beyond week 16. PASI 100 (completely clear skin) rates increased from 33 to 41% at week 24 to 48 to 49% at week 52 across the two ADVANCE studies. No new safety signals were identified through 52 weeks of treatment.

Safety Profile

Across the ICONIC clinical program, icotrokinra demonstrated what the FDA and independent reviewers characterized as a placebo-like safety profile at week 16, with adverse event rates within 1.1 percentage points of placebo. No new safety signals emerged through 52 weeks of follow-up.

Common adverse events reported in trials:

Headache
Nausea
Cough
Mild fungal infections (predominantly oral candidiasis)
Upper respiratory tract infection
Fatigue

Key safety considerations from the prescribing information:

Tuberculosis screening is required before initiating icotrokinra, consistent with other immunomodulating therapies. Live vaccines should not be administered during treatment. Providers should monitor for signs and symptoms of infection throughout the treatment course.

The absence of the elevated cardiovascular risk signals observed with some JAK inhibitors, and the absence of the hepatic or hematologic monitoring requirements associated with older systemic therapies like methotrexate, are practical clinical advantages in a patient population that often has cardiovascular comorbidities.

Dosing and Administration

Dose: 200 mg once daily
Timing: Upon waking, at least 30 minutes before eating
Method: One tablet swallowed with water. For patients who have difficulty swallowing tablets, the tablet may be dispersed in at least 120 mL of water; administration should be completed within 15 minutes of dispersion
Who is eligible: Adults and adolescents aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy

Where Icotrokinra Fits in Psoriasis Treatment

Current treatment guidelines from the American Academy of Dermatology recommend a stepwise approach. Topical therapies are typically first-line for mild disease. Systemic therapy becomes appropriate when topical treatments fail or disease is classified as moderate to severe.

For systemic therapy, the options now include:

Conventional systemic agents: methotrexate, cyclosporine, acitretin. Effective but carry significant monitoring burdens and toxicity profiles
Apremilast (Otezla): oral PDE4 inhibitor. Modest efficacy, generally better tolerated than conventional systemic agents
Deucravacitinib (Sotyktu): oral TYK2 inhibitor. More effective than apremilast, now demonstrated to be less effective than icotrokinra on primary endpoints
Biologic therapies targeting IL-17 or IL-23: highest efficacy class but require injection (ixekizumab, secukinumab, guselkumab, risankizumab, bimekizumab, others)
Icotrokinra (ICOTYDE): oral IL-23R peptide. Efficacy on primary endpoints exceeds prior oral options and approaches biologic-level response rates in some analyses

Icotrokinra’s approval creates a new clinical decision point for prescribers who have patients with moderate to severe disease who prefer or require oral treatment but have not achieved adequate responses on apremilast or deucravacitinib, or who want to avoid injectable biologics.

Whether icotrokinra will move earlier in the treatment sequence, potentially as first-line systemic therapy, will depend on payer formulary decisions, prescriber adoption patterns, and the results of the ongoing ICONIC-ASCEND trial (NCT06934226), which compares icotrokinra to ustekinumab (an IL-12/23 biologic) and will provide the first direct head-to-head data versus an injectable biologic.

For Patients

If you have moderate to severe plaque psoriasis and are currently on a systemic therapy that is not achieving adequate control, or if you have been reluctant to try injectable biologics, icotrokinra adds a clinically meaningful new oral option to the conversation you can have with your dermatologist.

It is not a replacement for injectable biologics in patients who are doing well on those regimens. It is an alternative for patients for whom oral treatment is preferable, for whom prior oral therapies were insufficient, or who are appropriate candidates for first-line systemic therapy.

Patient support is available through Johnson & Johnson’s ICOTYDE withMe program, which provides cost assistance options and educational resources. Information on eligibility and enrollment is available at icotyde.com.

The National Psoriasis Foundation maintains current information on all approved psoriasis treatments, including patient perspectives, treatment decision support tools, and a healthcare provider directory for finding dermatologists with psoriasis expertise. The American Academy of Dermatology’s “Find a Dermatologist” tool is a reliable starting point for patients seeking specialist care.

For related coverage of first-in-class oral therapies across different conditions in 2026, see our post on Foundayo (orforglipron), the first non-peptide oral GLP-1 receptor agonist approved for weight management, which represents a parallel story of oral formulation innovation changing a treatment landscape previously dominated by injectables.

Sources

FDA approval announcement: FDA approves icotrokinra for moderate to severe plaque psoriasis. FDA.gov. March 18, 2026.

Johnson & Johnson approval press release: FDA Approval of ICOTYDE (icotrokinra) Ushers in New Era for First-Line Systemic Treatment of Plaque Psoriasis. jnj.com. March 18, 2026.

ICONIC-ADVANCE 1 and 2 primary publication: Gold LS, Armstrong A, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. The Lancet. 2025. doi:10.1016/S0140-6736(25)01576-4.

ICONIC-LEAD 24-week data: Phase 3 Findings Suggest Icotrokinra Effective in Adults, Adolescents with Psoriasis. HCPLive. January 2026.

52-week data press release: ICOTYDE (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile. PRNewswire. March 28, 2026.

ICONIC-TOTAL scalp/genital data: Icotrokinra long-term results affirm promise in difficult-to-treat scalp and genital psoriasis. JNJ Investor. October 2025.

Dermatology Times approval coverage: FDA Approves Icotrokinra, First Oral IL-23 Receptor Blocker for Psoriasis. Dermatology Times. April 2026.

HMP Global approval summary: FDA Approves Icotyde for Moderate-to-Severe Plaque Psoriasis. HMP Global Learning Network. March 2026.

Rheumatology Advisor ICONIC-LEAD data: FDA Approves Oral Icotrokinra for Moderate to Severe Plaque Psoriasis. Rheumatology Advisor. March 2026.

ICONIC trial registrations: ICONIC-ADVANCE 1 (NCT06143878) | ICONIC-ADVANCE 2 (NCT06220604) | ICONIC-LEAD (NCT06095115) | ICONIC-TOTAL (NCT06095102)

Deucravacitinib FDA approval: FDA approves deucravacitinib for plaque psoriasis. FDA.gov.

Apremilast FDA approval: FDA approves apremilast for psoriatic arthritis. FDA.gov.

IL-23 pathway reference: IL-23 and psoriasis pathogenesis. PMC6429360.

Biologic therapy review: IL-17 and IL-23 pathway inhibition in psoriasis. PMC7460559.

Patient resources: National Psoriasis Foundation | AAD Find a Dermatologist | ICOTYDE patient support

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about psoriasis treatment, including whether icotrokinra is appropriate for your situation, should be made in consultation with a board-certified dermatologist who can evaluate your individual disease characteristics, treatment history, and comorbidities.

April 10, 2026

Generic Dapagliflozin Is Here. For 40 Million Americans With Type 2 Diabetes, That’s a Big Deal.

📌 The essentials The FDA has approved the first generic versions of dapagliflozin (Farxiga) tablets, the first SGLT2 inhibitor to reach generic status in the United States. Multiple generic manufacturers received approval simultaneously. Available doses: 5 mg and 10 mg tablets. Generic approval covers: type 2 diabetes (glycemic control and cardiovascular risk reduction) and reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and cardiovascular disease or multiple cardiovascular risk factors. The brand-name Farxiga retains additional approved indications (heart failure with preserved ejection fraction, chronic kidney disease) that the generics do not yet carry. Current approximate pricing: brand-name Farxiga runs $550 to $650 per month without insurance; generic dapagliflozin is running approximately $290 to $410 per month with discount coupons (GoodRx, SingleCare) as of April 2026. Confirm current pricing at GoodRx.com/dapagliflozin as prices will continue to change with market competition. Verify therapeutic equivalence: check the FDA Orange Book to confirm which manufacturers have received “AB” ratings, indicating interchangeability.

If you have been prescribing or taking Farxiga (dapagliflozin) for any length of time, you already know the conversation that tends to come up at refill time: the price. Without insurance, a 30-day supply of brand-name Farxiga runs between $550 and $650 per month. For a medication that many patients need to take daily and indefinitely, that is a meaningful barrier. The FDA’s approval of the first generic versions of dapagliflozin tablets changes that equation.

Multiple generic manufacturers have received approval simultaneously, and while generic pricing is not always as low as patients hope immediately after launch, the competitive pressure that comes with multiple manufacturers is what ultimately drives costs down. This is how the generic drug system is supposed to work.

Dapagliflozin: More Than a Diabetes Drug

Dapagliflozin belongs to a class of medications called SGLT2 inhibitors, short for sodium-glucose cotransporter 2 inhibitors. The mechanism is straightforward: the kidneys normally filter glucose from the blood and then reabsorb almost all of it back into circulation. SGLT2 inhibitors block the transporter protein responsible for that reabsorption, so excess glucose gets excreted in the urine instead. Lower blood glucose, less cardiovascular strain, less kidney filtration burden.

What made dapagliflozin and its SGLT2 classmates remarkable, and what eventually transformed both cardiology and nephrology practice, was what came out of the cardiovascular outcomes trials that the FDA mandated for all new diabetes drugs after 2008. Researchers expected to show the drugs were not harmful. What they found instead was that they were actively protective: significantly reducing hospitalizations for heart failure and slowing kidney disease progression, even in patients without diabetes.

The DAPA-HF trial, published in the New England Journal of Medicine in 2019, showed dapagliflozin reduced a composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with heart failure with reduced ejection fraction, including patients who did not have type 2 diabetes. The DAPA-CKD trial showed it reduced risk of a sustained decline in kidney function, end-stage kidney disease, or death from kidney or cardiovascular causes by 39% in patients with chronic kidney disease, again including non-diabetic patients. These were not minor findings. They were class-redefining.

The indications that dapagliflozin currently carries, and what the generic covers Dapagliflozin’s full FDA-approved indication list includes: type 2 diabetes in adults (glycemic control plus cardiovascular risk reduction); reduction of risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors; heart failure with reduced ejection fraction (regardless of diabetes status); heart failure with preserved ejection fraction; and chronic kidney disease in adults at risk of progression. The generic approval currently covers the type 2 diabetes and heart failure hospitalization risk reduction indications specifically. The additional heart failure and CKD indications remain on the brand label but are not yet part of the generic labeling. As the evidence base matures, generic labeling may expand to match. For the complete current list, the FDA prescribing information is the authoritative source.

Why Generic Approval Matters More for This Drug Than Most

Type 2 diabetes affects more than 40 million Americans, with 90 to 95% of all diabetes cases falling into this category. It is a condition that disproportionately affects lower-income populations and communities of color, exactly the populations for whom a $600-per-month medication is least accessible.

Despite its strong evidence base, adoption of SGLT2 inhibitor therapy in clinical practice has remained well below what guidelines recommend, and cost is consistently cited as a primary barrier. A 2025 review in npj Metabolic Health and Disease noted this explicitly, pointing to cost and clinician familiarity as the two main obstacles to uptake of a drug class with clear guideline support for reducing cardiovascular and kidney disease burden.

Generic availability does not immediately solve the cost problem, but it starts the clock. With discount coupons through services like GoodRx or SingleCare, generic dapagliflozin is currently available in the range of $290 to $410 per month for a 30-day supply, compared to $550 to $650 for the brand. That is a meaningful improvement, though still not cheap. As more manufacturers enter the market over the coming months, prices should continue to fall.

Current approximate price landscape (30-day supply):

Option	Without Insurance	With Discount Coupon
Brand-name Farxiga	$550 to $650/month	~$288 (GoodRx)
Generic dapagliflozin	$400 to $500/month	$290 to $410 (GoodRx/SingleCare)
With commercial insurance	Varies by plan	Copay $0 to $75 typical
AZ&Me patient assistance	Potentially $0	Eligibility required

AZ&Me is AstraZeneca’s patient assistance program for brand-name Farxiga. Patients who meet income eligibility can receive free medication. Details at azandme.com. Generic dapagliflozin is not covered under this program. Pricing figures are approximate as of April 2026 and subject to change.

What “Therapeutic Equivalence” Actually Means

A common question when a generic is approved: is it really the same? The short answer is yes, with a specific technical meaning. The FDA requires generics to demonstrate bioequivalence: they must deliver the same active ingredient in the same form, at the same dose, producing the same blood levels over the same time frame as the brand. The inactive ingredients (fillers, binders, coatings) can differ, which occasionally matters for patients with specific allergies or sensitivities, but the therapeutic effect is required to be equivalent.

Generics approved under this standard receive an “AB” rating in the FDA’s Orange Book, the Approved Drug Products database, indicating they are interchangeable at the pharmacy level without requiring a new prescription. You can check the Orange Book at accessdata.fda.gov/scripts/cder/ob/ to confirm which manufacturers have received approval and their equivalence rating.

Safety: The Generic Carries the Same Label

Generic dapagliflozin carries the same prescribing information, contraindications, warnings, and precautions as brand-name Farxiga. These are worth knowing, particularly for patients or prescribers newer to this drug class.

Contraindications

Known serious hypersensitivity to dapagliflozin or any excipient in the formulation
eGFR below the threshold specified in the label for the relevant indication (review the current label for the specific eGFR cutoffs by indication)

Key warnings to discuss with patients

Diabetic ketoacidosis (DKA): Can occur even with near-normal blood glucose (euglycemic DKA), a well-documented and sometimes underrecognized risk. Patients should be counseled to hold dapagliflozin before surgery and to recognize DKA symptoms including nausea, vomiting, abdominal pain, fatigue, and difficulty breathing.

Volume depletion: The osmotic diuretic effect can cause dehydration and hypotension, particularly relevant in older patients or those on diuretics. Assess volume status before initiating in high-risk patients.

Urinary tract and genital infections: The glucosuria that makes SGLT2 inhibitors effective also creates a more hospitable environment for yeast and bacterial infections. Genital mycotic infections are common, particularly in women. Counsel patients to report symptoms and maintain good hygiene.

Fournier’s gangrene: A rare but serious necrotizing fasciitis of the genitalia has been reported across the SGLT2 class. Patients with symptoms including pain, tenderness, redness, or swelling in the genital or perineal area should seek immediate care.

Lower limb amputations: A risk signal first identified with canagliflozin. The signal for dapagliflozin is less clearly established but warrants monitoring in high-risk patients including those with peripheral arterial disease or diabetic neuropathy.

As the SGLT2 class StatPearls reference notes, despite the substantial clinical advantages of this drug class, therapy requires attention to safety considerations including volume depletion, genital infections, diabetic ketoacidosis, and potential lower extremity complications. These are established safety signals, not new or unexpected findings with the generic.

A note on perioperative management SGLT2 inhibitors should generally be held before scheduled surgery due to the risk of euglycemic DKA. The recommended hold period varies by guideline. The ADA recommends holding for at least 3 to 4 days prior to major surgery. This is a counseling point worth building into any practice that prescribes dapagliflozin, especially now that more patients may receive it via generic without a specialist involved in initiation.

The Bigger Picture: Where This Drug Class Is Heading

Generic dapagliflozin’s arrival coincides with a remarkable moment for this drug class. SGLT2 inhibitors, initially developed as diabetes drugs, have become foundational therapies in cardiology and nephrology, a transformation that has happened faster than almost any comparable pharmacological shift in recent memory.

The 2024 to 2025 research cycle extended the evidence base further, with large meta-analyses showing benefits in acute myocardial infarction, acute decompensated heart failure, and non-diabetic chronic kidney disease without albuminuria. Trials are now exploring effects on cognitive decline, atrial fibrillation, and liver disease. Next-generation SGLT2-based compounds and dual SGLT1/SGLT2 inhibitors are in Phase II development.

There is also the Medicare context. Dapagliflozin and empagliflozin were selected as two of the first drugs for price negotiation under the Inflation Reduction Act, with negotiated prices taking effect in 2026. Generic competition and Medicare negotiation happening simultaneously represent an unusual convergence of affordability pressure on a single drug class. If that convergence translates to real-world access, it could meaningfully reduce the burden of undertreated cardiovascular and kidney disease in the populations that carry the highest risk.

For related coverage on how access to GLP-1 medications is being broadened through higher-dose approvals, see our post on Wegovy HD and the STEP UP trial data. For a parallel access story in diabetes care, our post on GLP-1 medications and PCOS covers how prescribing patterns in metabolic disease are shifting rapidly beyond original approved indications.

What to Watch Going Forward

Supply and availability

As of early 2026, generic manufacturers are still ramping up to full production capacity, which means spotty availability at some pharmacies, particularly in smaller markets. Calling ahead before a patient makes a trip to the pharmacy is practical advice worth passing along. Drug availability search tools like Medfinder can also help patients locate stock in real time.

Insurance formulary adjustments

Generic approval often triggers formulary changes. Some insurance plans may shift from covering brand-name Farxiga to preferring the generic, or may adjust tier placement. Patients on Farxiga who are told their insurance no longer covers it or covers it differently should check their updated formulary rather than assume the drug is not covered at all. Generic dapagliflozin should be therapeutically equivalent and typically at lower cost.

Expanding indications for the generic

The current generic approval covers type 2 diabetes and heart failure hospitalization risk reduction. As the evidence base continues to mature for heart failure with preserved ejection fraction and chronic kidney disease, it is worth watching whether FDA labeling for generic dapagliflozin expands to match the brand’s full approved indications.

Sources

FDA announcement: FDA Approves First Generic Dapagliflozin Tablets. FDA.gov.

Farxiga original FDA approval (T2D/CV): FDA approves dapagliflozin to reduce risk of hospitalization for heart failure in adults. FDA.gov.

Farxiga full prescribing information: Dapagliflozin prescribing information. accessdata.fda.gov.

Orange Book: FDA Approved Drug Products with Therapeutic Equivalence Evaluations. accessdata.fda.gov.

FDA generic drug bioequivalence: Generic Drug Facts. FDA.gov.

DAPA-HF trial: McMurray JJV et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008.

DAPA-CKD trial: Heerspink HJL et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-1446.

SGLT2 inhibitor class reference: Padda IS et al. Sodium-Glucose Transport 2 (SGLT2) Inhibitors. StatPearls. Updated September 2025.

Next-generation SGLT2 compounds: Cohen TD et al. Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives. Biomedicines. 2026;14(1):81.

Access barriers review: SGLT2 inhibitors across various patient populations in the era of precision medicine. npj Metabolic Health and Disease. 2025.

Inflation Reduction Act Medicare negotiation: Medicare Drug Price Negotiation. CMS.gov.

FDA cardiovascular outcomes trial guidance: Guidance for Industry: Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies. FDA.gov.

Fournier’s gangrene safety communication: FDA Drug Safety Communication: Rare but serious infection of the genitals and area around them. FDA.gov.

ADA perioperative guidance: Diabetes Care in the Hospital. ADA Standards of Care 2023.

Pricing tools: GoodRx: dapagliflozin | SingleCare: dapagliflozin

Patient assistance: AstraZeneca AZ&Me Program. azandme.com.

CDC type 2 diabetes: Type 2 Diabetes. CDC.gov.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Drug pricing information reflects approximate figures at time of publication and is subject to change. Always consult a qualified healthcare provider or pharmacist regarding medication decisions, including decisions about switching from a brand-name product to its generic equivalent.

April 9, 2026

That Itch That Won’t Quit: Inside the FDA Approval That PBC Patients Have Been Waiting For

📌 The essentials On April 22, 2026, the FDA approved Lynavoy (linerixibat, GSK), an oral ileal bile acid transporter (IBAT) inhibitor, for cholestatic pruritus in adults with primary biliary cholangitis (PBC). This is the first FDA-approved therapy specifically indicated for cholestatic pruritus in PBC. It is a full approval, not accelerated, meaning the FDA reviewed actual clinical benefit data. The clinical basis: the Phase 3 GLISTEN trial (NCT03706547) enrolling 238 patients with moderate to severe cholestatic pruritus, showing statistically significant reduction in worst itch NRS score versus placebo (p less than 0.001), with rapid onset by week 2 and benefit sustained through 24 weeks. Sleep quality also improved significantly (p=0.024). Key safety consideration: diarrhea occurred in 61% of patients in GLISTEN, the majority mild to moderate. Discontinuation rate due to diarrhea was approximately 4%. What it does not do: Lynavoy is not a disease-modifying therapy for PBC. It does not slow liver disease progression or replace existing PBC treatments including UDCA or obeticholic acid. It treats the itch.

There is a particular kind of suffering that does not show up well on a lab report. Cholestatic pruritus, the relentless, internal itch caused by bile acid accumulation in primary biliary cholangitis, is one of them. It does not scratch away. It does not respond to antihistamines. It keeps patients awake at 3 a.m., disrupts concentration, and compounds the psychological weight of already managing a progressive autoimmune liver disease.

On April 22, 2026, the FDA approved Lynavoy (linerixibat), GSK’s oral IBAT inhibitor, specifically for cholestatic pruritus in adults with PBC. It is the first medicine approved in the United States for this indication. As approvals go, this is one where the clinical evidence and the patient need are unusually well-aligned.

What Is Primary Biliary Cholangitis?

PBC is a rare, chronic autoimmune liver disease in which the immune system mistakenly attacks the small bile ducts inside the liver. As those ducts are damaged and scarred over time, bile cannot drain properly; it backs up into the liver and eventually into the bloodstream.

The disease affects roughly 1 in 1,000 women over 40, though it is underdiagnosed and can affect men as well. Without effective management, PBC can progress to cirrhosis, liver failure, and the need for transplantation.

Cholestatic pruritus affects up to 89% of people with PBC at some point during the disease. It is caused by the accumulation of bile acids in the skin and blood, and it is notoriously difficult to treat. Before Lynavoy, available options were largely off-label, inconsistently effective, and sometimes poorly tolerated. For many patients, managing the itch meant cycling through treatments that did not really work.

How Linerixibat Works

Linerixibat is an ileal bile acid transporter (IBAT) inhibitor. Under normal circumstances, the IBAT protein in the small intestine reabsorbs bile acids from the gut back into circulation, a recycling loop that keeps the body’s bile acid pool stocked. In PBC, where the liver is already struggling to process that pool, this recycling makes the problem worse.

Linerixibat blocks the IBAT pump in the gut, preventing that reabsorption. Fewer bile acids recirculate. Levels in the blood and skin drop. And for many patients, so does the itch.

It is a targeted, mechanistically rational approach. Because it acts locally in the gut rather than systemically, it avoids some of the side effects associated with older therapies like cholestyramine.

Why does blocking gut bile acid recycling help with itch in the skin? Bile acids that recirculate from the gut end up in systemic blood, and from there accumulate in peripheral tissues including the skin. The exact mechanism by which bile acids trigger itch is not fully established; it likely involves bile acid receptors on sensory nerve fibers, specifically the TGR5 receptor and the bile acid-sensitive ion channel TRPA1. The clinical correlation between bile acid levels and itch severity is well-documented. Reducing the circulating load through IBAT inhibition targets the source of the symptom rather than suppressing the itch signal downstream.

The GLISTEN Trial: What the Data Shows

The pivotal GLISTEN Phase 3 trial (NCT03706547) enrolled 238 patients with PBC and moderate to severe cholestatic pruritus. Participants were randomized to linerixibat or placebo for 24 weeks. The primary endpoint was itch intensity, measured using the Numerical Rating Scale (NRS) for worst itch, a validated patient-reported outcome that captures what patients actually experience rather than a laboratory surrogate.

Endpoint	Result	Statistical significance
Worst itch NRS reduction vs. placebo	Statistically significant mean difference	p less than 0.001
Sleep quality improvement (NRS)	Significant improvement vs. placebo	p=0.024
Onset of itch benefit	Detectable by week 2	—
Duration of benefit	Sustained through 24 weeks	—
Diarrhea (all grade)	61% in linerixibat arm	Discontinuation rate ~4%
Abdominal pain	18% in linerixibat arm	Discontinuation rate less than 1%

Source: GLISTEN Phase 3 trial, NCT03706547. GSK press release, April 22, 2026.

The sleep quality finding deserves equal weight as the itch reduction data. In qualitative research and patient surveys, pruritus-related sleep disruption consistently ranks as one of the most burdensome aspects of PBC, sometimes more so than concerns about disease progression. A therapy that demonstrably improves both itch intensity and sleep quality is addressing the full clinical picture of what patients report as most disruptive to their daily lives.

The diarrhea rate of 61% is notable and warrants clear communication with patients before initiating therapy. Most cases were mild to moderate, and the discontinuation rate of approximately 4% was low, but this is a side effect that will affect real-world tolerability, particularly for patients who are already managing fatigue and GI sensitivity as part of their PBC picture. Clinicians prescribing Lynavoy will need to set expectations carefully and discuss management strategies, including dose timing, dietary considerations, and when dose adjustment is appropriate.

The full approval status matters here. This is not accelerated approval based on a surrogate biomarker. The FDA reviewed patient-reported outcome data on actual symptom reduction and determined it met the standard for substantial evidence of clinical benefit. That is a meaningful regulatory bar, and the GLISTEN data cleared it.

Dr. Christopher Bowlus, Chief of Gastroenterology and Hepatology at UC Davis Health and a principal investigator in the linerixibat program, characterized the approval as representing an important opportunity to improve the lives of people with PBC who struggle with uncontrolled and often debilitating pruritus. That framing reflects the clinical reality: “uncontrolled and often debilitating” is not hyperbole in this patient population.

What This Approval Does Not Answer

Does treating the itch affect disease progression?

Lynavoy is approved specifically for symptom management, not as a disease-modifying therapy for PBC itself. Patients with PBC who need a medication to slow liver disease progression are managed with ursodeoxycholic acid (UDCA) or obeticholic acid. Linerixibat does not replace those. Whether there is any long-term hepatoprotective effect from reducing bile acid recirculation has not been established and should not be assumed from the GLISTEN data, which was not designed or powered to assess disease progression.

Real-world tolerability

Trial populations tend to be healthier and more closely monitored than the broader patient population. The 61% diarrhea rate in GLISTEN will bear watching in post-market use, particularly in older patients or those with baseline GI sensitivity who were not well represented in the trial. Patient registries and observational data over the next one to two years will be more informative here than the trial data alone.

Cost and access

Lynavoy carries Orphan Drug Designation, which typically supports premium pricing and seven years of market exclusivity. GSK has not yet announced U.S. list pricing. For a symptom-focused therapy in a rare disease, the cost-benefit calculus for payers is different than for a life-prolonging treatment, which could create coverage access hurdles worth monitoring. GSK’s patient support program details will matter significantly for patients navigating these conversations.

The Broader Context: IBAT Inhibitors and Cholestatic Liver Disease

Linerixibat’s approval in adult PBC is part of a broader story in hepatology. The IBAT inhibitor mechanism has already demonstrated clinical utility in pediatric cholestatic conditions. Maralixibat (Livmarli) is approved for cholestatic pruritus in Alagille syndrome, and odevixibat (Bylvay) is approved for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC). The validation of this mechanism in adult PBC extends the evidence base for IBAT inhibition across cholestatic conditions and may support future investigation in other forms of cholestatic liver disease where pruritus remains inadequately managed.

Lynavoy is also GSK’s first FDA-approved liver medicine from its hepatology pipeline, reflecting a deliberate strategic move for a company historically stronger in respiratory and immunology. A partnership with Alfasigma S.p.A. covers global commercialization, with regulatory submissions underway in the EU, UK, Canada, and China. Whether this represents a durable GSK hepatology platform or a single-indication program will become clearer as the pipeline matures.

For context on how the FDA approaches safety monitoring for rare disease liver conditions, see our coverage of the Tavneos (avacopan) serious liver injury warning and the ongoing regulatory dispute between the FDA and Amgen over voluntary withdrawal.

For Patients and Caregivers

For adults living with PBC and cholestatic pruritus who have not achieved adequate itch relief with currently available treatments, Lynavoy adds the first indication-specific approved option in the United States. The conversation about whether it is appropriate for an individual patient belongs with a gastroenterologist or hepatologist who is familiar with the full picture of disease activity, current medications, and GI tolerance.

The PBCers Organization is the primary U.S. patient advocacy group for primary biliary cholangitis and has responded to the Lynavoy approval as a significant step forward for those dealing with chronic, uncontrolled itch. Their resources, community forums, and physician directory are the best starting point for patients navigating this diagnosis. The American Liver Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases also maintain current clinical information on PBC management.

The GLISTEN trial is complete. Ongoing clinical trials for PBC and cholestatic liver disease can be searched at ClinicalTrials.gov for patients interested in research participation.

Sources

GSK FDA approval press release: GSK Announces U.S. FDA Approval of Lynavoy (linerixibat), the First and Only Medicine Approved in the US Specifically for Cholestatic Pruritus in Adults with Primary Biliary Cholangitis (PBC). April 22, 2026. gsk.com.

GLISTEN trial registration: NCT03706547. A Phase III Study to Evaluate the Efficacy and Safety of Linerixibat in Participants with Primary Biliary Cholangitis with Cholestatic Pruritus. ClinicalTrials.gov.

PBC epidemiology and pruritus burden: Primary Biliary Cholangitis: Epidemiology and Quality of Life. PMC7510845.

Cholestatic pruritus overview: Cholestatic Pruritus. StatPearls. NCBI.

IBAT inhibitor mechanism: Ileal Bile Acid Transporter Inhibitors as a Novel Therapeutic Approach. PMC7387516.

UDCA in PBC: Ursodeoxycholic Acid. StatPearls. NCBI.

Obeticholic acid FDA approval: FDA approves obeticholic acid for primary biliary cholangitis. FDA.gov.

Maralixibat FDA approval: FDA approves maralixibat chloride for Alagille syndrome. FDA.gov.

Odevixibat FDA approval: FDA approves odevixibat for pruritus in cholestatic liver disease. FDA.gov.

PBC NIDDK overview: Primary Biliary Cholangitis. NIDDK.

Orphan Drug Designation: Designating an Orphan Product. FDA.gov.

Patient resources: PBCers Organization | American Liver Foundation: PBC | NIDDK PBC | ClinicalTrials.gov: PBC pruritus

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about PBC treatment, including whether linerixibat is appropriate for your situation, should be made in consultation with a qualified gastroenterologist or hepatologist familiar with your individual disease status, treatment history, and current medications.

April 8, 2026

Ovarian Cancer Has Resisted Almost Every Drug Thrown at It in the Platinum-Resistant Setting. Lifyorli™ Just Changed That by Targeting Cortisol.

📌 The essentials On March 25, 2026, the FDA approved Lifyorli (relacorilant, Corcept Therapeutics) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval based on overall survival data, not accelerated approval. The mechanism: relacorilant is an oral, selective glucocorticoid receptor (GR) antagonist. It blocks cortisol’s tumor-protective action that suppresses apoptosis in cancer cells, sensitizing them to nab-paclitaxel’s cytotoxic effect. Dosing: relacorilant 150 mg orally on the day before, day of, and day after each nab-paclitaxel infusion, given in 28-day cycles. The clinical basis: Phase 3 ROSELLA trial (NCT05257408), published in The Lancet, showing median overall survival of 16.0 versus 11.9 months (HR 0.65; p=0.0004), a 35% reduction in risk of death. The 18-month OS rate was 46% versus 27%. NCCN has designated relacorilant plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer.

For roughly thirty years, the story of platinum-resistant ovarian cancer has been one of persistent failure. Trial after trial. Checkpoint inhibitor after checkpoint inhibitor. PARP inhibitor combinations. Antibody-drug conjugates. Antiangiogenics beyond bevacizumab. The disease has resisted almost everything, and the graveyard of Phase 3 trials that failed in this setting is long and dispiriting.

Platinum-resistant ovarian cancer is defined by a clinical reality: the cancer progresses within six months of completing platinum-based chemotherapy. At that point, the treatment options narrow sharply. Single-agent non-platinum chemotherapy, including pegylated liposomal doxorubicin, paclitaxel, gemcitabine, and topotecan, with or without bevacizumab, has been the mainstay. Response rates are modest. Survival is poor.

On March 25, 2026, the FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is the first FDA-approved selective glucocorticoid receptor antagonist, a category of drug that does not target the tumor directly, but instead targets the role cortisol plays in helping tumors resist the chemotherapy meant to kill them. The pivotal ROSELLA trial, published simultaneously in The Lancet, delivered something this disease has not seen in a long time: a statistically robust overall survival improvement.

The Disease: Why Platinum-Resistant Ovarian Cancer Is So Hard to Treat

Ovarian cancer is the most lethal gynecologic malignancy. In 2024, an estimated 320,000 new cases were diagnosed globally and approximately 210,000 women died from the disease, accounting for about 4.8% of all cancer-related mortality. In the United States, ovarian cancer kills approximately 12,800 women annually. The high mortality relative to incidence reflects a disease that is typically diagnosed at advanced stage (III or IV), when cure is unlikely.

Platinum-based chemotherapy, carboplatin and cisplatin, has been the backbone of ovarian cancer treatment for three decades. Most patients initially respond well. The problem is recurrence: approximately 70% of patients with advanced ovarian cancer will relapse, and through successive platinum cycles, resistance becomes inevitable. Once a patient’s cancer progresses within six months of the last platinum regimen, they are classified as platinum-resistant, and the therapeutic landscape changes dramatically for the worse.

Why this setting has been so difficult: the failed trials The list of Phase 3 trials that failed to improve overall survival in platinum-resistant ovarian cancer is extensive. Checkpoint inhibitors have largely disappointed in ovarian cancer despite transforming outcomes in melanoma, lung cancer, and other solid tumors. The ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab versus chemotherapy, was negative. The underlying biology is partially explanatory: ovarian tumors often have immunosuppressive microenvironments with low T-cell infiltration, limited PD-L1 expression, and mechanisms that actively exclude immune cells. Notably, the ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab plus paclitaxel plus or minus bevacizumab in platinum-resistant ovarian cancer did ultimately produce the first significant PFS and OS benefit with immunotherapy in this setting. That approval, covered here on Health Evidence Digest, required PD-L1 CPS of 1 or higher for the indicated population. For patients who do not meet that biomarker threshold or who have progressed after immunotherapy, the unmet need remained enormous. What was needed for that broader population was a different angle of attack entirely.

The Mechanism: Cortisol as a Shield for Tumor Cells

The biological rationale for relacorilant starts with a question that oncologists have long observed but had limited tools to address: why does chemotherapy work initially in ovarian cancer, then stop working? Part of the answer involves the tumor microenvironment, and specifically the role cortisol plays within it.

Cortisol is a glucocorticoid hormone produced by the adrenal glands that regulates stress responses, inflammation, and immune function. In normal physiology, cortisol plays many important and beneficial roles. In tumor biology, however, cortisol, acting through the glucocorticoid receptor (GR) expressed in many cancer cell types, contributes to chemotherapy resistance through a specific and well-characterized mechanism: it inhibits apoptosis.

Apoptosis is programmed cell death, the cellular self-destruct mechanism that chemotherapy is specifically designed to trigger. Taxane chemotherapies like nab-paclitaxel work by disrupting microtubule function during cell division, causing mitotic arrest and ultimately apoptotic cell death. When cortisol activates GR signaling in tumor cells, it suppresses the apoptotic machinery, effectively giving those cells a cortisol-mediated shield against the chemotherapy that should be killing them.

Relacorilant is an oral, selective glucocorticoid receptor antagonist. It competes with cortisol at the GR binding site, blocking the receptor without activating it. With GR signaling suppressed, cortisol’s protection of tumor cells from apoptosis is reduced, and the tumor cells become more sensitive to nab-paclitaxel’s intended mechanism. Relacorilant is selective: it binds only to the glucocorticoid receptor, not to the progesterone, androgen, mineralocorticoid, or estrogen receptors. This selectivity is what distinguishes it from older, non-selective glucocorticoid antagonists like mifepristone.

The dosing schedule and why it matters for tolerability Relacorilant is taken orally at 150 mg on three specific days per 28-day cycle: the day before each nab-paclitaxel infusion, the day of the infusion, and the day after. Nab-paclitaxel is administered intravenously on days 1, 8, and 15 of each cycle. This intermittent dosing design is intentional. Continuous glucocorticoid receptor blockade would interfere with the body’s normal cortisol-dependent functions, including immune regulation, glucose metabolism, and stress response. By limiting GR blockade to the three days surrounding each chemotherapy infusion, the regimen specifically targets the period when cortisol’s tumor-protective effects are most relevant, while minimizing disruption to normal physiology. This design choice is supported by the trial’s safety data: no cases of adrenal insufficiency were reported in the ROSELLA trial.

The ROSELLA Trial: Design and Full Results

The Phase 3 ROSELLA trial (NCT05257408) was an international, randomized, controlled, open-label study conducted across 117 sites in 14 countries, including the United States, multiple European nations, South Korea, Brazil, Argentina, Canada, and Australia, in collaboration with the GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG. Enrollment ran from January 2023 to April 2024.

Patient population

Eligible patients were adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, defined as disease progression within six months of the last platinum-based therapy. All had received one to three prior systemic therapy regimens, and all had prior bevacizumab exposure. Patients requiring chronic corticosteroids were excluded. The median patient age was 61 to 62 years.

Randomization and treatment

381 patients were randomized 1:1 to relacorilant 150 mg plus nab-paclitaxel 80 mg/m² (n=188), or nab-paclitaxel alone at 100 mg/m² (n=193). The monotherapy arm received a higher dose of nab-paclitaxel to reflect the absence of a chemo-sensitizing partner. The dual primary endpoints were progression-free survival (PFS) by RECIST 1.1 and blinded independent central review, and overall survival.

Results

Endpoint	Relacorilant plus nab-paclitaxel	Nab-paclitaxel alone
Median overall survival	16.0 months (95% CI 13.0 to 18.3)	11.9 months (95% CI 10.0 to 13.8)
OS hazard ratio	0.65 (95% CI 0.51 to 0.83)	Reference
OS p-value	0.0004	—
Reduction in risk of death	35%	—
12-month OS rate	60%	50%
18-month OS rate	46%	27%
Median PFS (BICR)	6.5 months (95% CI 5.6 to 7.4)	5.5 months (95% CI 3.9 to 5.9)
PFS hazard ratio	0.70 (95% CI 0.54 to 0.91)	Reference
PFS p-value	0.0076	—
Reduction in risk of progression	30%	—
12-month PFS rate	25%	13%
Second PFS (PFS2) hazard ratio	0.73 (p=0.0037)	Reference

Source: Olawaiye AB et al. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9. ROSELLA trial (NCT05257408).

The OS data maturity at the final analysis was 76%, meaning three-quarters of patients had experienced the endpoint, making this a robust and interpretable dataset. The Lancet publication notes that the Kaplan-Meier survival curves show progressively widening separation over time, suggesting durable benefit rather than early separation that converges. The 18-month OS rate difference — 46% versus 27% — is particularly striking: at 18 months, nearly half of patients on the combination were still alive, compared with just over one-quarter on chemotherapy alone.

The benefit was consistent across all prespecified subgroups, including patients who had received two versus three prior lines of therapy, those with prior PARP inhibitor exposure, and across geographic regions. No biomarker selection was required for eligibility or benefit, which means the improvement applies to the broad platinum-resistant ovarian cancer population, not a molecularly defined subset.

The principal investigator of the ROSELLA trial, Dr. Alexander B. Olawaiye, MD, Director of Gynecologic Cancer Research at Magee-Womens Hospital of UPMC, characterized the finding at the SGO Late-Breaker presentation as the first demonstration that modulating the steroid receptor pathway, specifically the glucocorticoid receptor, can produce benefit in the treatment of platinum-resistant ovarian cancer, noting that the uniqueness of the pathway makes this new in every way.

Safety: What the Data Shows

The combination arm had a higher rate of grade 3 or higher treatment-emergent adverse events than the monotherapy arm: 74.5% versus 59.5%. The primary driver was hematologic toxicity, particularly neutropenia (44% versus 25% in the combination arm) and anemia (18% versus 9%). These findings reflect the addition of any chemotherapy-sensitizing agent and are consistent with what clinicians encounter in other combination regimens.

Adverse event (20% or higher incidence)	Combination arm	Monotherapy arm
Decreased hemoglobin	Most common, all grades	Lower rate
Neutropenia (grade 3 or higher)	44%	25%
Fatigue	20% or higher	Present
Nausea	20% or higher	Present
Diarrhea	20% or higher	Present
Decreased platelets	20% or higher	Present
Rash	20% or higher	Present
Decreased appetite	20% or higher	Present
Anemia (grade 3 or higher)	18%	9%
Adrenal insufficiency	0 cases	0 cases
Deaths attributed to relacorilant	0	0

Two specific safety findings deserve emphasis. First, no cases of adrenal insufficiency were observed, validating the intermittent dosing design. Second, peripheral neuropathy, a known concern with taxane chemotherapy, occurred at similar rates in both arms, suggesting relacorilant did not worsen this chemotherapy-related toxicity.

The prescribing label carries a contraindication for patients who require corticosteroids for a life-saving indication, because GR blockade would impair their effectiveness. Patients on systemic corticosteroids for severe asthma, inflammatory bowel disease, or immunosuppression following transplant require careful evaluation before initiating Lifyorli. Prescribing information warnings include neutropenia and severe infection risk, adrenal insufficiency monitoring, exacerbation of conditions treated with glucocorticoids, and embryo-fetal toxicity.

What This Approval Represents

The NCCN Clinical Practice Guidelines in Oncology added Lifyorli plus nab-paclitaxel as a preferred regimen for platinum-resistant ovarian cancer following the approval. That designation reflects the committee’s assessment that the overall survival data from ROSELLA represents a meaningful advance for a patient population with very limited meaningful advances over the past decade.

Three aspects of the ROSELLA data deserve specific emphasis as markers of robustness. The OS analysis is mature: 76% data maturity is high for an ongoing survival analysis and ensures the hazard ratio estimate is reliable. Subsequent therapies were balanced between the two arms, ruling out the possibility that post-progression treatment differences explain the survival benefit. And the benefit was consistent across all predefined subgroups, including those heavily pretreated and those with prior PARP inhibitor exposure.

What we do not yet know: open questions for clinical practice No biomarker predicted response. ROSELLA enrolled without biomarker selection and found benefit across all subgroups. That is good news for broad access, but it means there is not yet a way to identify which patients are most likely to respond, or whether some patients have particularly high GR expression that drives greater benefit. Corcept and academic collaborators are likely studying this as a post-approval research question. Patient-reported quality of life. The ROSELLA trial included EORTC quality-of-life measures as secondary endpoints. Full patient-reported outcome analysis had not been comprehensively presented at time of writing. For patients in this setting, tolerability and quality of remaining life matter alongside survival data. Relacorilant in other tumor types. Corcept has active or planned trials of relacorilant in platinum-sensitive ovarian cancer, endometrial cancer, cervical cancer, pancreatic cancer, and prostate cancer. The proof-of-concept from ROSELLA that GR antagonism can sensitize tumors to chemotherapy may accelerate these programs.

Regulatory Status and Access

FDA approval

Approved March 25, 2026, for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. This is a full approval, based on overall survival data from ROSELLA meeting both co-primary endpoints.

European Medicines Agency

Corcept has submitted a Marketing Authorisation Application (MAA) to the EMA for relacorilant in platinum-resistant ovarian cancer. Relacorilant has received orphan drug designation from the European Commission for ovarian cancer treatment. The EMA review is ongoing.

Patient support

Corcept has established Lifyorli Support for patients and healthcare providers at 1-855-439-6754 (1-85-LIFYORLI). For questions about eligibility, prior authorization support, or financial assistance programs, this is the recommended first contact.

For patients and families navigating platinum-resistant ovarian cancer, the Ovarian Cancer Research Alliance and the Foundation for Women’s Cancer both maintain updated treatment information, clinical trial directories, and peer support resources. For related HED coverage of ovarian cancer treatment advances in 2026, see our post on pembrolizumab becoming the first approved immunotherapy for platinum-resistant ovarian cancer and our analysis of vepdegestrant and the PROTAC mechanism in breast cancer as examples of how novel mechanisms of action are reshaping gynecologic and breast oncology in the same period.

Sources

FDA approval: FDA approves relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. FDA.gov. March 25, 2026.

Corcept press release (approval): FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist. ir.corcept.com. March 25, 2026.

Corcept press release (SGO/OS data): Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet. ir.corcept.com. April 10, 2026.

Primary OS publication: Olawaiye AB et al. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial. The Lancet. 2026. doi:10.1016/S0140-6736(26)00462-9

PFS publication: Lorusso D et al. ROSELLA: a phase 3 study of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. The Lancet. 2025;405:2205-2216.

ROSELLA trial registration: NCT05257408. ClinicalTrials.gov.

CancerNetwork OS coverage: Relacorilant/Nab-Paclitaxel Reduces Risk of Death by 35% in Platinum-Resistant Ovarian Cancer. cancernetwork.com. April 2026.

CURE coverage: Lifyorli Combo Approved in Platinum-Resistant Ovarian Cancer. curetoday.com. March 2026.

Targeted Oncology: Relacorilant Demonstrates Significant OS in Platinum-Resistant Ovarian Cancer. targetedonc.com. April 2026.

PROC treatment landscape: Current Treatments, Future Strategies for Platinum-Resistant Ovarian Cancer. AJMC. March 2026.

PROC unmet need review: Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance. PubMed. 2023. PMID:37079311.

NCCN guidelines: Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. NCCN.

Glucocorticoid receptor biology: Glucocorticoid Receptor Signaling in Cancer. PMC7694440.

Apoptosis reference: Apoptosis. StatPearls. NCBI.

Cortisol overview: Cortisol. StatPearls. NCBI.

RECIST/PFS methodology: New Response Evaluation Criteria in Solid Tumours. PMC3107543.

Checkpoint inhibitors in ovarian cancer: Immune Checkpoint Inhibitors in Ovarian Cancer. PMC7174922.

PARP inhibitors: PARP Inhibitors. cancer.gov.

Neutropenia: Neutropenia. StatPearls. NCBI.

Patient resources: Ovarian Cancer Research Alliance | Foundation for Women’s Cancer | NCCN Ovarian Cancer Guidelines | Lifyorli Support: 1-855-439-6754

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for platinum-resistant ovarian cancer should be made in consultation with a qualified gynecologic oncologist.

April 6, 2026

GLP-1 Drugs and Suicidal Thoughts: The FDA Reviewed 107,910 Patients and 2.2 Million Real-World Users. What It’s Now Asking Drug Makers to Remove.

📌 Where This Review Stands as of January 2026: Read This First January 13, 2026: The FDA issued an updated Drug Safety Communication concluding that its comprehensive review, spanning 91 clinical trials, 107,910 patients, and a real-world cohort of 2.24 million users, found no evidence of increased suicidal behavior or ideation with GLP-1 receptor agonists. The FDA has formally requested removal of suicidality warnings from the prescribing information for semaglutide, tirzepatide, and liraglutide. This is the FDA’s clearest signal that it considers the concern resolved. The European Medicines Agency reached a similar conclusion in April 2024 after its own independent review. Important nuance: the FDA’s update also examined anxiety, depression, irritability, and psychosis, and found no increased risk for these psychiatric adverse events either. Patients should not stop GLP-1 medications without consulting their healthcare provider. If you are experiencing mood changes or distressing thoughts, contact your clinician and call or text 988.

When a drug is used by tens of millions of people, any signal in the adverse event database draws attention, even when that signal does not establish causation. That is the story of how GLP-1 receptor agonists and suicidality became a major pharmacovigilance question, why it took more than two years and two regulatory agencies to work through the evidence, and why the answer that emerged from one of the largest drug safety analyses ever conducted matters for patients and clinicians navigating this question.

The conclusion: the FDA reviewed the evidence systematically and comprehensively. It found no causal link. It is now asking manufacturers to remove the suicidality warning language. Getting to that conclusion required understanding why the signal appeared, why it was worth investigating seriously, and why the initial reports did not mean what some feared.

How the Signal Emerged and Why It Was Worth Investigating

GLP-1 receptor agonists, the class that includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and others, have become among the most widely prescribed drugs in modern medicine. More than 40 million Americans have taken semaglutide alone. At that scale, rare adverse events generate measurable counts in pharmacovigilance databases even when those events occur at the same rate as in untreated patients.

The concern originated in Europe. In 2023, the European Medicines Agency received reports of suicidal thoughts and self-injury in patients taking semaglutide and liraglutide. The EMA initiated a formal safety review. The FDA, which had already added precautionary language to certain GLP-1 labels, also began a systematic evaluation. In January 2024, the FDA announced preliminary findings with no evidence of a causal link, but stated the review was not yet complete. The January 13, 2026 Drug Safety Communication represents the completed review.

Why the initial signal was plausible enough to investigate seriously Several biological mechanisms made a GLP-1/suicidality connection worth examining. GLP-1 receptors are expressed not just in the pancreas and gut but throughout the brain, including in regions involved in mood regulation, reward processing, and appetite. Semaglutide is known to reduce what is sometimes described as “food noise,” the intrusive, preoccupying thoughts about food. Whether this appetite-suppressing CNS effect could, in some patients, contribute to a broader hedonic blunting or mood change was a reasonable hypothesis to test. Additionally, rapid weight loss from any cause is associated with increased risk of mood disruption, nutritional deficiency, and in some cases a paradoxical worsening of psychological wellbeing when results do not match expectations. Patients who begin GLP-1 therapy with unrealistic expectations and experience slower-than-expected weight loss may be particularly vulnerable. An umbrella review published in Healthcare (MDPI) in 2025 specifically identified unrealistic treatment expectations as a factor associated with suicidal ideation in GLP-1 users, independently of any pharmacological mechanism. The precedent from lorcaserin (Belviq), a weight-loss drug withdrawn in 2020 due to cancer risk that had also carried a suicidality warning, created additional regulatory pressure to examine this class carefully. And context matters: obesity and type 2 diabetes both independently elevate the baseline risk of depression and suicidality, meaning any population study in GLP-1 users is working against a backdrop of elevated baseline risk.

What the FDA’s Review Actually Examined

The January 2026 Drug Safety Communication represents one of the most comprehensive pharmacovigilance analyses ever conducted for a drug class. The FDA’s review incorporated three distinct streams of evidence.

1. FAERS adverse event report review

The FDA conducted detailed reviews of suicidal thoughts and action reports in its Adverse Event Reporting System (FAERS) database. It found that the reports were limited in detail and that suicidal events could be explained by other factors, including the underlying conditions for which GLP-1s are prescribed. A peer-reviewed FAERS analysis by McIntyre et al. (2024), applying Bradford Hill criteria for causality assessment, found disproportionate reporting of suicidal ideation with semaglutide and liraglutide, but no disproportionate reporting of actual suicidal behavior, suicide attempts, or completed suicide for any GLP-1. Their conclusion: no causal link exists when confounders are considered.

2. Meta-analysis of 91 clinical trials (107,910 patients)

The FDA conducted a meta-analysis pooling data from 91 placebo-controlled clinical trials of GLP-1 medications: 60,338 patients treated with GLP-1s and 47,572 treated with placebo. This is among the largest drug safety meta-analyses ever assembled for a single question. The results did not demonstrate an increased risk of suicidal behavior or ideation with GLP-1s. The analysis also examined related psychiatric outcomes, including anxiety, depression, irritability, and psychosis, and found no increased risk for any of these either.

3. Sentinel System real-world cohort study (2.24 million users)

The FDA’s Sentinel System, a large database of health insurance claims and patient health records, was used to conduct a retrospective cohort study comparing the risk of intentional self-harm between new users of GLP-1 receptor agonists and new users of SGLT2 inhibitors. The study included 1,161,983 GLP-1 users and 1,081,155 SGLT2 users. This real-world analysis found no increased risk of intentional self-harm with GLP-1 use.

Evidence stream	Scale	Finding
FAERS adverse event review	Detailed case-by-case review	No clear causal relationship; limited report detail; events explainable by underlying conditions
Clinical trial meta-analysis	91 trials, 107,910 patients (60,338 GLP-1 vs 47,572 placebo)	No increased risk of suicidal ideation, behavior, anxiety, depression, irritability, or psychosis
Sentinel real-world cohort	2,243,138 users (1.16M GLP-1 vs 1.08M SGLT2 inhibitor)	No increased risk of intentional self-harm with GLP-1 use
EMA independent review (April 2024)	EU-based pharmacovigilance and clinical trial data	Evidence insufficient to support causal association; no label change warranted

Beyond the FDA: What Independent Research Shows

The regulatory conclusions are consistent with the direction of the independent peer-reviewed literature, which has grown substantially since 2023.

The Nature Medicine study (semaglutide vs. comparators, n=240,618)

A study published in Nature Medicine, led by researchers at Case Western Reserve University and the National Institute on Drug Abuse, used electronic health records from 240,618 patients with overweight or obesity prescribed semaglutide or a non-GLP-1 medication for weight management. Semaglutide was associated with a lower risk of incident suicidal ideation (HR 0.27) and recurrent suicidal ideation (HR 0.44) compared with other agents. Dr. Nora Volkow, MD, Director of the National Institute on Drug Abuse (NIDA), was explicit about the appropriate interpretation of this finding in the publication’s commentary: the study does not indicate that taking semaglutide could reduce the risk of suicidal ideation or that it actively protects against suicidal ideation, as such a conclusion would require clinical trials.

Mendelian randomization: no genetic link

A Mendelian randomization study by Nguyen (2024) used genetic variants associated with GLP-1 pathway activity as proxies for long-term drug-like exposure. This approach can detect causal biological effects independent of confounders. The study found no causal evidence linking the glycemic and BMI-lowering effects of GLP-1 receptor agonists to an increased risk of suicide attempts, either in the general population or in individuals with pre-existing mental health conditions.

Systematic reviews and meta-analyses

A 2025 systematic review in Diabetes/Metabolism Research and Reviews (Bushi et al.) pooled observational cohort and case-control studies. It found no consistent association between GLP-1 use and increased suicidal ideation or behavior in the general diabetes or obesity population. An umbrella review published in Healthcare (MDPI) in 2025 synthesized 12 reviews and meta-analyses and found results consistent across studies, with no significant association between GLP-1 use and suicidality. A meta-analysis of 31 RCTs involving approximately 85,000 patients found no significant difference in psychiatric disorders (OR 0.97; 95% CI 0.83 to 1.15) or suicidal behavior (OR 0.86) between GLP-1 and placebo arms.

The Critical Confounding Issue: Obesity and Diabetes Independently Elevate Suicide Risk

This point deserves its own section because it is the single most important piece of context for interpreting any report connecting GLP-1 drugs to suicidality.

Obesity is independently associated with elevated rates of depression, anxiety, and suicidal ideation. Type 2 diabetes is independently associated with the same. People prescribed GLP-1 receptor agonists are, by definition, drawn from a population with higher baseline risk of psychiatric adverse events than the general population. When a drug is given to millions of people from a higher-risk population, adverse events including suicidal ideation will be reported, even if the drug itself plays no causal role.

This is called confounding by indication: the condition being treated (obesity, diabetes) is itself a risk factor for the outcome being studied (suicidal ideation). Properly controlled studies, using comparator groups of patients with the same underlying conditions on different medications, or using the Mendelian randomization approach to remove confounders entirely, consistently fail to find excess suicidal risk attributable to GLP-1 drugs.

The co-prescription signal: a nuance worth knowing One finding from the Bushi et al. systematic review warrants specific clinical attention: patients co-prescribed antidepressants showed a substantially higher reporting odds ratio for suicidal ideation (ROR 4.45; 95% CI 2.52 to 7.86), and those co-prescribed benzodiazepines showed a similarly elevated signal (ROR 4.07; 95% CI 1.69 to 9.82). This suggests that individuals with pre-existing mental health conditions who are also taking GLP-1 drugs may warrant closer psychiatric monitoring. This does not mean GLP-1 drugs caused the suicidality in these patients. It almost certainly reflects the fact that patients already on antidepressants or benzodiazepines have higher baseline psychiatric vulnerability. But it is a reasonable clinical signal: if a patient is already being treated for depression or anxiety and starts a GLP-1, maintaining existing mental health follow-up is sensible practice regardless of the FDA’s label change.

What the FDA Is Asking Drug Makers to Remove and What Stays

The January 2026 Drug Safety Communication is explicit: the FDA is requesting removal of suicidal behavior and ideation warnings from the prescribing information for semaglutide, tirzepatide, and liraglutide. This is a formal regulatory request to manufacturers, not a unilateral FDA label change. Manufacturers submit the proposed language and the FDA approves it. The practical effect is the same.

What stays in the label: the established, class-wide safety profile for GLP-1s including gastrointestinal effects, thyroid C-cell tumor risk for injectable GLP-1s, pancreatitis risk, and the contraindications relevant to each specific drug. None of these are affected by the suicidality review.

The FDA also emphasized that despite requesting label removal, clinicians should continue to be prepared to discuss the findings with patients and to refer individuals who report suicidal ideation or behavior to mental health professionals, not because the drug is causing it, but because the population taking these drugs has higher baseline psychiatric risk that warrants clinical awareness.

For Patients: What This Means in Practice

Do not stop your GLP-1 medication based on the suicidality concern. The evidence does not support a causal link. Stopping abruptly without medical guidance can worsen blood sugar control or cause rebound weight gain. Read our post on what happens when semaglutide is discontinued for more context on managing GLP-1 therapy transitions.

Do tell your prescribing clinician about any changes in mood, new or worsening depression, or distressing thoughts. This applies to any medication in any patient and is not specific to GLP-1s, but it is always important to keep your care team informed.

If you already have a history of depression or anxiety, ensure your mental health provider is aware you are starting a GLP-1. Not because of a drug risk, but because any significant metabolic change, body image shift, or treatment expectation mismatch can affect mental health in people already managing psychiatric conditions.

If you are having thoughts of self-harm or suicide, call or text 988 (U.S. Suicide and Crisis Lifeline) any time, or go to your nearest emergency department. Do not wait for a scheduled appointment.

The label change does not mean GLP-1 drugs are risk-free. They have well-documented side effects including gastrointestinal effects, injection site reactions, and for some patients, hair loss. The specific concern about suicidality, however, has been investigated extensively and not confirmed.

For Clinicians: Practical Takeaways

The FDA’s label change request does not eliminate the clinical rationale for psychiatric monitoring in GLP-1 users. The population prescribed these drugs has elevated baseline psychiatric risk, and the co-prescription signal (antidepressants, benzodiazepines) warrants awareness even if it likely reflects underlying vulnerability rather than a drug effect.

Discuss realistic treatment expectations before initiating GLP-1 therapy. The umbrella review found that unrealistic expectations and disappointment with weight loss results were associated with elevated suicidal risk signals. Setting evidence-based expectations, specifically that 10 to 15% weight loss is typical and results vary, is now both good clinical practice and supported by the safety literature.

The review’s psychiatric adverse event finding is broader than suicidality. No increased risk of anxiety, depression, irritability, or psychosis was found across 91 trials. This is useful context for reassuring patients who ask about neuropsychiatric effects broadly.

For patients with a history of suicidality or active psychiatric illness who are candidates for GLP-1 therapy, consider co-management with their mental health provider, not because of drug risk but because of the baseline complexity.

For related HED coverage of GLP-1 medications and their evolving indications, see our posts on GLP-1 medications and PCOS fertility research in 2026, the approval of Wegovy HD (semaglutide 7.2 mg) and the STEP UP trial data, and the FDA’s post-marketing study requirements for Foundayo (orforglipron).

If you or someone you know is struggling with mental health right now, please reach out to the 988 Suicide and Crisis Lifeline by calling or texting 988, available 24 hours a day, 7 days a week in the U.S.

Sources

FDA Drug Safety Communication (Jan 2026): Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking Certain Type 2 Diabetes and Obesity Medicines. January 13, 2026. fda.gov.

Pharmacy Times coverage: FDA Finds No Increased Suicide Risk With GLP-1 Medications, Requests Removal of Warning Labels. pharmacytimes.com. 2026.

EMA review conclusion: European Medicines Agency. Assessment report on GLP-1 receptor agonists and risk of suicidal behavior and ideation. April 2024.

McIntyre et al. FAERS analysis: McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. Association between GLP-1 RAs and suicidality using Bradford Hill criteria. Expert Opin Drug Saf. 2024;23(1):47-55. doi:10.1080/14740338.2023.2295397

Nature Medicine cohort: Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024. doi:10.1038/s41591-023-02750-1

Bushi et al. systematic review: Bushi G et al. Association of GLP-1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta-Analysis. Diabetes Metab Res Rev. 2025. doi:10.1002/dmrr.70037

Umbrella review: Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence. Healthcare (MDPI). 2025;13(22):2958. doi:10.3390/healthcare13222958

ScienceDirect systematic review: The effect of GLP-1 receptor agonists on measures of suicidality: A systematic review. ScienceDirect. 2025. doi:10.1016/j.jad.2025.01.007

Lancet eClinical case-time-control: Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study. EClinicalMedicine. 2024. doi:10.1016/j.eclinm.2024.102983

Mendelian randomization: Nguyen et al. Causal assessment of GLP-1 RA effects and suicide attempts via Mendelian randomization. 2024.

FDA Sentinel System: FDA’s Sentinel Initiative. fda.gov/safety/fdas-sentinel-initiative.

Bradford Hill criteria reference: Bradford Hill Criteria. PMC4589481.

GLP-1 receptor agonist overview: GLP-1 Receptor Agonists. StatPearls. NCBI.

SGLT2 inhibitor overview: SGLT2 Inhibitors. StatPearls. NCBI.

Crisis resources: 988 Suicide and Crisis Lifeline. 988lifeline.org. Call or text 988, available 24/7.

Disclaimer: Health Evidence Digest provides general information about drug safety research for educational purposes. This content is not a substitute for professional medical advice. If you are experiencing thoughts of self-harm or suicide, contact 988 or seek emergency care immediately. Do not stop prescribed medications without consulting your healthcare provider.

April 5, 2026

The KRESLADI Trial Data That Just Earned the First Gene Therapy Approval for LAD-I

📌 The essentials On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel, Rocket Pharmaceuticals), the first gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I), indicated specifically for pediatric patients who lack an available HLA-matched sibling donor. The clinical basis: a Phase 1/2 trial (NCT03812263) enrolling 9 children with molecularly confirmed severe LAD-I, showing 100% HSCT-free survival at one year (95% CI 66 to 100; p less than 0.001), 0 graft failures, and sustained neutrophil CD18 expression through median 4.2-year follow-up. Results published in the New England Journal of Medicine. This is an accelerated approval based on biomarker surrogates (CD18 and CD11a expression). Confirmatory post-marketing studies are required. Rare Pediatric Disease Priority Review Voucher granted alongside approval. The boxed warning: lentiviral vector-mediated insertional oncogenesis, requiring long-term post-treatment monitoring.

Most children born with severe Leukocyte Adhesion Deficiency Type I do not survive to their second birthday without treatment. Their white blood cells, the immune system’s first responders, lack a critical surface protein called CD18 that allows them to exit the bloodstream and reach the site of infection. Without it, bacteria and fungi go virtually unchallenged. The infections are relentless, poorly responsive to antibiotics, and frequently fatal. Omphalitis, infection of the umbilical stump, is sometimes the first sign, in a newborn just days old.

The only curative option before March 2026 was an allogeneic hematopoietic stem cell transplant from an HLA-matched sibling donor. Most children do not have one. Transplants from mismatched donors carry substantial risks: graft failure, graft-versus-host disease, and transplant-related mortality. Some families faced a situation with no good path forward.

On March 26, 2026, the FDA approved KRESLADI (marnetegragene autotemcel), the first gene therapy for severe LAD-I, indicated specifically for pediatric patients without an available matched sibling donor. The clinical trial behind it enrolled nine children. None had graft failure. All survived. The youngest were infants; all who were enrolled under age one were alive beyond age two. The data was published in the New England Journal of Medicine.

Leukocyte Adhesion Deficiency Type I: What It Is and Why It Kills

LAD-I is caused by biallelic (two-copy) loss-of-function mutations in the ITGB2 gene, which encodes CD18, the beta-2 integrin subunit that pairs with CD11 proteins to form integrin complexes on the surface of leukocytes. These CD11/CD18 complexes, particularly LFA-1, composed of CD11a and CD18, are what allow white blood cells to adhere to the inner walls of blood vessels and migrate through them into infected tissues. Without functional CD18, neutrophils and other leukocytes stay in circulation. They cannot reach wounds. They cannot engulf bacteria at infection sites. Infections that a healthy immune system would clear in days become life-threatening emergencies.

Severe LAD-I is defined by CD18 surface expression below 2% of normal. At this level, even minor infections, a skin abrasion, a gum infection, the umbilical cord stump, can become life-threatening. The infection burden is compounded by delayed wound healing: without leukocyte migration, the inflammatory cascade needed for tissue repair does not function properly.

How rare is LAD-I? The incidence of LAD-I in the U.S. is estimated at approximately 1 in 100,000 to 1 in 200,000 live births. Roughly two-thirds of affected patients have the severe form. Based on approximately 3.6 million U.S. births per year, that translates to roughly 12 to 24 new cases of severe LAD-I annually in the United States. Global prevalence is higher in regions where consanguineous marriage is more common, as LAD-I is autosomal recessive, meaning a child must inherit one mutated ITGB2 copy from each parent. In some Middle Eastern and South Asian populations, the disease burden is proportionally higher. The ultra-rarity of the disease is part of why gene therapy development has been slow: a clinical trial enrolling 9 patients represents a meaningful fraction of the total global patient population who meet enrollment criteria at any given time.

How KRESLADI Works: Lentiviral Gene Correction of the Patient’s Own Stem Cells

KRESLADI is an autologous gene therapy, meaning it is manufactured from the patient’s own cells, corrected in the laboratory, and returned to the same patient. This eliminates the core risk of donor-based transplantation: immune mismatch. There is no foreign tissue to reject, and no graft to mount an attack against the host.

The manufacturing process follows a sequence of steps before the patient receives a single intravenous infusion:

Mobilization and apheresis: The patient receives drugs (G-CSF and/or plerixafor) to mobilize hematopoietic stem cells (HSCs) from the bone marrow into the bloodstream. These CD34+ progenitor cells are then collected by apheresis, a process that filters blood through a machine and harvests stem cells.

Ex vivo gene correction: The harvested CD34+ cells are taken to a manufacturing facility and transduced with a lentiviral vector carrying a functional copy of the ITGB2 gene. The lentiviral vector integrates into the cell genome, providing a permanent genetic correction. A back-up collection of unmodified CD34+ cells is preserved in case engraftment fails.

Myeloablative conditioning: Before infusion, the patient undergoes full myeloablative conditioning, high-dose chemotherapy designed to eliminate the existing defective bone marrow and create space for the corrected cells to engraft. This is a significant clinical intervention and the primary source of short-term treatment-related risk.

Infusion: The gene-corrected cells are infused intravenously in a single dose. They travel to the bone marrow, engraft, and begin producing CD18-expressing neutrophils and other leukocytes, ideally for the patient’s lifetime.

Lentiviral vectors and insertional oncogenesis: the long-term risk to understand A lentiviral vector works by integrating a copy of the therapeutic gene into the patient’s genome, which is what makes the correction permanent. But integration is not perfectly targeted: the vector can insert near oncogenes (cancer-promoting genes), potentially disrupting their regulation. This risk is called insertional oncogenesis. Early-generation retroviral gene therapies for X-linked SCID caused leukemia in some patients, creating lasting concern about the category. Modern lentiviral vectors like the one used in KRESLADI are self-inactivating (SIN): the viral promoter that could drive oncogene expression is deleted after integration, substantially reducing this risk. The prescribing information for KRESLADI includes a formal warning for lentiviral vector-mediated insertional oncogenesis and requires long-term follow-up monitoring. No cases of insertional oncogenesis were observed in the Phase 1/2 trial, but with a median follow-up of 4.2 years in only 9 patients, long-term surveillance remains a post-marketing requirement. This is not a reason to avoid the therapy in a disease with near-certain early mortality without treatment, but it is a reason for enrolled families to maintain follow-up.

The Phase 1/2 Clinical Trial: Nine Patients, Published in NEJM

The trial supporting KRESLADI’s approval (NCT03812263) was an open-label, single-arm, multicenter Phase 1/2 study conducted at leading pediatric immunodeficiency centers including UCLA and Great Ormond Street Hospital in London. It enrolled 9 children with molecularly confirmed severe LAD-I (biallelic ITGB2 mutations, CD18 expression below 2% of normal) who lacked an available HLA-matched sibling donor.

The primary endpoints were biomarker-based: neutrophil CD18 and CD11a surface expression at 12 and 24 months, used as surrogates for restored immune function. Secondary endpoints included safety, engraftment, infection events, and HSCT-free survival. Results were published in the New England Journal of Medicine.

Outcome	Result
Study population	9 children with severe LAD-I, biallelic ITGB2 mutations, no HLA-matched sibling donor
HSCT-free survival at 1 year	100% (95% CI 66 to 100; p less than 0.001)
Graft failures	0 of 9
Median follow-up	4.2 years (range 3.6 to 5.7)
Neutrophil CD18 expression (Month 12)	Sustained increase in all 9 patients
Neutrophil CD18 expression (Month 42)	Sustained in all 7 patients with available data
Neutrophil CD11a expression (Month 12)	Median 45% (range 18 to 75)
Neutrophil CD11a expression (Month 24)	Median 39% (range 17 to 65)
Patients enrolled below age 1 year	All alive beyond 2 years of age
Treatment-related serious adverse events	None reported
Insertional oncogenesis cases	None observed (ongoing monitoring required)

Source: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

The 100% HSCT-free survival figure warrants careful interpretation alongside the confidence interval (66 to 100%). With only 9 patients, the lower bound of that confidence interval means the true survival rate could theoretically be as low as 66%, which is not a negligible uncertainty. The FDA’s accelerated approval based on biomarker data rather than confirmed long-term clinical outcomes reflects this: the agency considered the surrogate endpoints (CD18 and CD11a expression) sufficiently likely to predict clinical benefit given the biological coherence and the disease’s natural history, while requiring confirmatory data through post-marketing studies.

What the 4.2-year median follow-up confirms is durability of the biomarker response: all 7 patients with data available at month 42 maintained sustained neutrophil CD18 expression. The correction appears stable across the observation period, which is among the longest available for any lentiviral hematopoietic gene therapy in a primary immunodeficiency.

Vinay Prasad, MD, MPH, Chief Medical and Scientific Officer and Director of the FDA Center for Biologics Evaluation and Research, stated at the time of approval that today’s accelerated approval provides a breakthrough treatment for pediatric patients with severe LAD-I, the first FDA-approved gene therapy to treat this disease.

KRESLADI vs. Allogeneic HSCT: Understanding the Comparison

The most meaningful clinical comparison for KRESLADI is not placebo. In a disease with near-certain early mortality, a placebo-controlled trial would be unethical. The relevant comparison is allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor, the only prior curative approach.

Feature	KRESLADI (gene therapy)	Matched sibling HSCT
Donor required	No, uses patient’s own cells	Yes, HLA-matched sibling
Availability	All eligible patients without matched sibling	Approximately 25 to 30% of patients have matched sibling
GVHD risk	None (autologous)	Significant, especially with mismatched donors
Graft failure risk	0 of 9 in trial	Higher with mismatched; lower with matched sibling
Conditioning required	Yes, full myeloablative	Yes, myeloablative or reduced-intensity
Insertional oncogenesis risk	Small but real (lentiviral vector)	None
Long-term follow-up data	Median 4.2 years (n=9)	Decades; large registry data available
Regulatory status	FDA accelerated approval (March 2026)	Standard curative approach (first-line when donor available)

The comparison highlights that KRESLADI is approved specifically for the gap population, those without an available HLA-matched sibling donor. It does not replace matched-sibling HSCT, which remains the standard approach when a donor is available. For families without that option, gene therapy now provides a curative path that did not previously exist.

The ongoing clinical evolution of HSCT is also worth noting. Haploidentical transplantation, using a partially matched donor such as a parent, is increasingly feasible through improved graft manipulation techniques and is being evaluated as an alternative for patients without matched siblings. The availability of KRESLADI creates an additional option alongside these evolving transplant approaches, giving clinicians and families more to consider.

Safety: What to Know Before Treatment

No treatment-related serious adverse events were reported in the Phase 1/2 trial, a notable finding given the severity of the conditioning regimen required. Most adverse reactions reflected the expected effects of myeloablative conditioning rather than the gene therapy product itself.

Common adverse reactions in the trial population included: mucositis, upper respiratory tract infection, viral infection, febrile neutropenia, skin lesions, nausea and vomiting, rash, pyrexia, device-related infection, decreased blood counts (hemoglobin, platelets, neutrophils, leukocytes), and elevated liver enzymes (AST, ALT).

The prescribing information includes formal warnings and precautions for:

Serious infections: susceptibility increases during the myeloablative conditioning period before engraftment is established
Veno-occlusive disease (hepatic VOD): monitor liver function tests during the first month following infusion
Neutrophil engraftment failure: defined as failure to achieve absolute neutrophil count of 500 cells per microliter or higher by Day 43; back-up unmodified CD34+ cells are preserved in case rescue is needed
Delayed platelet engraftment
Lentiviral vector-mediated insertional oncogenesis: long-term monitoring required
Hypersensitivity reactions

What Treatment Involves: The Full Patient Journey

For families whose child has been diagnosed with severe LAD-I and lacks an HLA-matched sibling donor, the path to KRESLADI involves a structured sequence of steps that requires specialized care at a qualified treatment center.

Genetic confirmation first

KRESLADI is indicated specifically for patients with severe LAD-I due to biallelic variants in ITGB2 confirmed by molecular testing, with CD18 expression below 2% of normal. Clinical diagnosis alone is not sufficient for eligibility. Genetic testing confirming the ITGB2 mutations is required.

Specialized treatment center

KRESLADI will be administered only at qualified treatment centers with experience in bone marrow transplantation and gene therapy. The manufacturing process, including mobilization, apheresis, ex vivo gene correction, and back-up cell preservation, requires institutional infrastructure that is not available at all pediatric centers. Rocket Pharmaceuticals indicated it plans a measured rollout to ensure quality and safety at launch.

Timing matters

The trial enrolled children as young as infants. Outcomes in LAD-I gene therapy, as in most gene therapies for primary immunodeficiencies, are generally better when treatment is given before significant infection-related damage has accumulated. Families who receive a diagnosis of severe LAD-I should contact a specialized immunodeficiency center promptly to discuss evaluation and next steps, rather than waiting for a clinical crisis.

Regulatory designations

KRESLADI received multiple FDA designations supporting its development:

With approval, Rocket Pharmaceuticals received a Rare Pediatric Disease Priority Review Voucher, a transferable regulatory instrument that entitles the holder to priority (6-month) FDA review for a future NDA or BLA. PRVs have historically traded in the $100 to $150 million range. Rocket may use the voucher for a future program or sell it; either way, it represents a financial mechanism designed to incentivize rare pediatric drug development.

For families whose child has been diagnosed with severe LAD-I or who are under evaluation for a primary immunodeficiency presenting with recurrent severe infections in infancy, the most important first step is early referral to a center with expertise in primary immunodeficiencies and gene therapy. The Immune Deficiency Foundation maintains a directory of immunodeficiency specialists and can connect families with clinical expertise. For questions about KRESLADI specifically, Rocket Pharmaceuticals’ medical affairs team and information on the treatment program are available through their website. The confirmatory post-marketing studies will build the long-term evidence base that the Phase 1/2 trial, while remarkable, cannot yet provide. Families who enroll in long-term follow-up contribute directly to that body of evidence.

Sources

FDA press release: FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I. FDA.gov. March 26, 2026.

Rocket Pharmaceuticals press release: Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe LAD-I. March 27, 2026. ir.rocketpharma.com.

FDA approval letter: BLA 125806/0 Approval Letter. March 26, 2026.

KRESLADI prescribing information: KRESLADI (marnetegragene autotemcel) Prescribing Information. Rocket Pharmaceuticals; 2026.

NEJM primary publication: Phase 1/2 clinical trial results for marnetegragene autotemcel in LAD-I. New England Journal of Medicine. NCT03812263.

Phase 1/2 trial registration: NCT03812263. Gene Therapy for Leukocyte Adhesion Deficiency Type I. ClinicalTrials.gov.

Pharmacy Times coverage: FDA Approves Marne-Cel, First Stem Cell-Based Gene Therapy for Pediatric Patients With LAD-I. pharmacytimes.com. March 2026.

Rheumatology Advisor: Gene Therapy Kresladi Approved for Severe Leukocyte Adhesion Deficiency-I. rheumatologyadvisor.com. March 2026.

BioPharm International: FDA Approval of Kresladi Expands Gene Therapy in Pediatric Rare Diseases. biopharminternational.com. April 2026.

Disease overview: Novoa EA et al. Leukocyte adhesion deficiency-I: A comprehensive review. J Allergy Clin Immunol Pract. 2018.

LAD-I GARD overview: Leukocyte Adhesion Deficiency Type 1. rarediseases.info.nih.gov.

CD18 biology: CD18 integrin biology. PMC5555401.

Lentiviral vectors: Lentiviral vectors in gene therapy. PMC6563422.

Insertional oncogenesis: Insertional oncogenesis risk in gene therapy. PMC8709598.

Hematopoietic stem cells: Hematopoietic Stem Cells. StatPearls. NCBI.

Myeloablative conditioning: Myeloablative Conditioning. StatPearls. NCBI.

Haploidentical HSCT: Haploidentical Transplantation. PMC7138706.

HLA matching in HSCT: HLA Matching in HSCT. StatPearls. NCBI.

Accelerated approval pathway: Accelerated Approval Program. FDA.gov.

Rare Pediatric Disease PRV: Rare Pediatric Disease Priority Review Voucher Program. FDA.gov.

Patient resources: Immune Deficiency Foundation | NORD: LAD-I | Rocket Pharmaceuticals | ClinicalTrials.gov: LAD-I

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions for severe LAD-I should be made in consultation with a board-certified pediatric immunologist or hematologist at a center with expertise in gene therapy and primary immunodeficiencies. KRESLADI received accelerated approval; continued approval may be contingent on confirmatory post-marketing study results.

April 5, 2026

Prolia Costs $2,500 a Dose. There Are Now 19 Biosimilar Competitors. Here’s What That Means for Patients.

📌 The essentials On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia (denosumab, Amgen) for all five of Prolia’s approved indications. Commercial launch expected Q3 2026. This is the 19th FDA-approved denosumab biosimilar, not the first. Several have already launched commercially in the United States with modest savings of approximately 5 to 15% below Prolia’s list price. Critical distinction for patients: PONLIMSI is approved as a biosimilar but does NOT have interchangeable designation. Only Jubbonti (Sandoz) has interchangeable status for Prolia, meaning only Jubbonti can be substituted by a pharmacist without calling your prescriber. Simultaneously, Teva announced that the FDA and EMA have both accepted regulatory filings for its proposed omalizumab (Xolair) biosimilar. This is not an approval; it is the start of review. A Prolia discontinuation warning: do not stop denosumab abruptly for any reason, including a transition to a biosimilar. Rebound vertebral fractures are a documented serious risk. Any transition must be clinician-guided.

Osteoporosis affects an estimated 200 million people globally and is responsible for approximately 9 million fractures per year worldwide. In the United States, about 10 million adults have osteoporosis and another 44 million have low bone density, putting them at elevated fracture risk. Hip fractures in older adults carry a one-year mortality rate of up to 36%, a statistic that makes bone health a genuine life-or-death clinical priority, not a cosmetic concern.

Denosumab (Prolia, Amgen) is one of the most effective medications available for high-risk osteoporosis. It reduces vertebral fracture risk by up to 68%, hip fractures by 40%, and nonvertebral fractures by 20% in clinical trials. It is also, without insurance, a $2,506 injection administered twice a year, making it inaccessible or unaffordable for many of the patients who need it most.

On March 30, 2026, Teva Pharmaceutical received FDA approval for PONLIMSI (denosumab-adet), a biosimilar to Prolia, and simultaneously announced that regulatory agencies in both the U.S. and Europe have accepted filings for its proposed biosimilar to Xolair (omalizumab), a biologic used in severe asthma, nasal polyps, and IgE-mediated food allergy. These are meaningful regulatory events, but they exist in a context that the original announcement does not capture: the denosumab biosimilar market is now crowded, savings to patients have been disappointingly modest so far, and understanding the difference between a biosimilar and an interchangeable biosimilar has real implications for whether your pharmacist can make the switch without calling your doctor.

What Denosumab Does and Why It Is So Expensive

Denosumab is a fully human monoclonal antibody that works by inhibiting RANKL, receptor activator of nuclear factor kappa-B ligand, a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for breaking down bone. By blocking RANKL, denosumab suppresses bone resorption, which allows bone mineral density to increase and fracture risk to fall.

Amgen markets denosumab under two brand names: Prolia (60 mg subcutaneous injection every 6 months) for osteoporosis and bone loss from hormonal cancer therapies, and Xgeva (120 mg every 4 weeks) for preventing skeletal-related events in patients with bone metastases and giant cell tumors. The two products use the same molecule but are approved for different indications at different doses.

The $2,500+ price per dose reflects the cost of biologic drug manufacturing. Denosumab is produced in living cells using complex, expensive processes, not synthesized chemically like a small molecule tablet. Amgen has generated approximately $2.9 billion annually from Prolia alone. Despite recent patent expirations in the U.S. and Europe opening the door to biosimilar competition, the denosumab market has yet to see the dramatic price reductions that biosimilar proponents hoped for.

A critical clinical nuance: the rebound fracture risk on discontinuation Denosumab has a well-documented risk of rebound vertebral fractures when treatment is stopped abruptly. Because denosumab’s anti-resorptive effect reverses quickly after the drug clears the system, faster than bisphosphonates which accumulate in bone tissue, stopping denosumab without transitioning to another therapy can produce a rapid spike in bone turnover that significantly increases fracture risk in the first 12 to 24 months after discontinuation. Multiple cases of simultaneous vertebral fractures following denosumab discontinuation have been reported in the literature. Current guidelines recommend that patients stopping denosumab for any reason, including switching to a biosimilar if the transition is not managed carefully, receive bridging therapy with a bisphosphonate. This is not a biosimilar-specific concern, but it is relevant for any patient or prescriber navigating a formulary switch or change in product.

PONLIMSI: What the Approval Is Based On

PONLIMSI (denosumab-adet) received FDA approval on March 30, 2026, based on a totality of evidence demonstrating comparable efficacy, safety, and immunogenicity to Prolia. This evidence includes data from a randomized, double-blind Phase 3 clinical trial (NCT04729621) enrolling 332 women with postmenopausal osteoporosis, comparing denosumab-adet directly against Prolia across these endpoints.

PONLIMSI is approved for all five indications of the reference product Prolia:

Indication	Patient Population
Postmenopausal osteoporosis	Women at high risk for fracture, including history of fracture or multiple risk factors; or failed or intolerant to other osteoporosis therapy
Male osteoporosis	Men at high risk for fracture
Glucocorticoid-induced osteoporosis	Men and women on long-term corticosteroid therapy at high risk for fracture
Prostate cancer bone loss	Men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
Breast cancer bone loss	Women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

The EMA granted marketing authorization for PONLIMSI in Europe in November 2025, meaning the drug had already been approved in the EU before its U.S. clearance. Teva has indicated a commercial launch in the United States is expected in Q3 2026.

The Critical Distinction: Biosimilar vs. Interchangeable and Why It Matters for Patients

This is the most practically important piece of information in this post, and it was absent from the original coverage of PONLIMSI’s approval.

In the United States, there are two categories of FDA-approved biosimilars: biosimilar and interchangeable biosimilar. The difference matters at the pharmacy counter.

	Biosimilar	Interchangeable Biosimilar
FDA standard	Highly similar to reference product; no clinically meaningful differences in safety, purity, potency	Same as biosimilar PLUS: can be substituted without the prescriber’s involvement
Pharmacy substitution	Cannot be substituted automatically; requires prescriber authorization or new prescription in most states	Can be substituted by pharmacist without calling the prescriber (subject to state pharmacy laws)
Benefit to payer and patient	May require step therapy or prior authorization to access lower cost	Formulary substitution can happen more easily, driving faster cost competition
PONLIMSI status	Biosimilar only, NOT interchangeable (as of approval)	Jubbonti (Sandoz) has interchangeable designation
Real-world implication	Prescriber or insurer action typically needed	Pharmacist can swap without a call to the prescriber

Teva’s announcement did not mention an interchangeability designation for PONLIMSI. This means that in most U.S. states, a pharmacist cannot automatically substitute PONLIMSI for Prolia based on a prescription for denosumab. A clinician or insurer action is typically required. Patients who want to access the biosimilar version may need to ask their provider to write a new prescription specifically for PONLIMSI, or navigate a formulary preference process through their insurer.

The Denosumab Biosimilar Landscape: 19 Approvals, Modest Savings

PONLIMSI is not entering an empty market. By the time it launches in Q3 2026, it will be one of at least 19 FDA-approved denosumab biosimilars. Eighteen were approved by the end of December 2025, with PONLIMSI the first addition in 2026. Several have already launched commercially in the United States.

Biosimilar	Company	FDA Status	Notes
Jubbonti / Wyost	Sandoz	Approved March 2024; launched June 2025	First to market; interchangeable designation; 14.5% below Prolia WAC
Osenvelt / Stoboclo	Celltrion	Launched July 2025	5 to 10% discount range reported
Jubereq / Osvyrti	Accord BioPharma	Launched October 2025	Competitive pricing
Enoby / Xtrenbo	Gedeon Richter / Hikma	Approved; not yet launched	—
Bilprevda / Bildyos	Henlius / Organon	Approved; not yet launched	—
PONLIMSI	Teva	Approved March 2026; Q3 2026 launch expected	No interchangeability designation announced

The savings picture has been a disappointment relative to earlier expectations. Sandoz’s Jubbonti, the first approved interchangeable denosumab biosimilar, launched in June 2025 at a list price approximately 14.5% below Prolia’s wholesale acquisition cost. Celltrion’s biosimilars entered at an estimated 5 to 10% discount. A published budget impact model in the Journal of Medical Economics projected savings of $0.59 per member per month for health plans at medium conversion rates over five years, meaningful at scale, but not the 50 to 80% price reductions that biosimilar competition drove in markets like Europe.

Why are U.S. denosumab biosimilar savings so modest compared to Europe? In the UK, biosimilar adoption within the first year of launch routinely exceeds 90% of market share, driven by NHS tender-based procurement and institutional formulary switches. British rheumatologist Dr. Muhammad Nisar noted to Medscape that clinicians feel very comfortable with denosumab biosimilars, with great belief in their efficacy and safety. In the U.S., the market structure is fundamentally different. Amgen has kept Prolia competitively priced through rebates to pharmacy benefit managers (PBMs) and insurers. The net price paid by many payers may already be below the biosimilar list price after rebates. This perverse dynamic, in which originator rebates can make a brand-name drug cheaper to a payer than the biosimilar list price, is a structural feature of the U.S. drug market that dampens biosimilar adoption and competition. The interchangeability designation matters here too. Only Sandoz’s Jubbonti has interchangeable status for Prolia, allowing direct pharmacy substitution. The other approved denosumab biosimilars, including PONLIMSI, require prescriber action or payer-directed formulary changes to reach patients, slowing the pace of market conversion.

The Xolair Biosimilar Filing: A Different Market, A Different Opportunity

Teva’s simultaneous announcement that both the FDA and EMA have accepted filings for its proposed biosimilar to Xolair (omalizumab, Genentech/Novartis) is a separate and strategically distinct event from the PONLIMSI approval.

What omalizumab is and who uses it

Omalizumab (Xolair) is a monoclonal antibody that works by binding to free IgE, immunoglobulin E, the antibody class central to allergic responses, and blocking its interaction with IgE receptors on mast cells and basophils. By reducing free IgE levels, omalizumab prevents the downstream allergic cascade that produces symptoms in atopic disease.

Xolair is approved in the U.S. for: moderate-to-severe persistent allergic asthma inadequately controlled by inhaled corticosteroids in patients 6 and older whose asthma is related to a perennial allergen; chronic rhinosinusitis with nasal polyps in adults; chronic spontaneous urticaria in patients whose symptoms are inadequately controlled by antihistamines; and IgE-mediated food allergies in patients 1 year and older. That food allergy indication, the most recent addition, significantly expanded the patient population that might use omalizumab.

The market context

Global omalizumab sales are estimated at $3.5 to $3.7 billion annually, making this a commercially meaningful biosimilar target. Regulatory filing acceptance by both FDA and EMA simultaneously means Teva’s submission was complete enough for substantive review. This is not an approval; it is the beginning of the regulatory review process. The FDA’s standard review clock for biosimilar applications is 12 months from acceptance.

The omalizumab biosimilar market is at an earlier stage than denosumab. The omalizumab biosimilar landscape will be watched carefully by allergists, pulmonologists, and patients with severe allergic disease who currently pay thousands of dollars per year for brand-name Xolair, a cost that is a meaningful access barrier for many.

What This Means in Practice: Guidance for Patients

If you are currently on Prolia or another denosumab product

Do not stop denosumab without a medical plan for what comes next. The rebound fracture risk on discontinuation is real and serious. Any transition to a biosimilar should be clinician-guided, maintaining the same dosing schedule (every 6 months for Prolia indications) and likely incorporating a bisphosphonate bridge if you stop denosumab for any reason.

If cost is a barrier to accessing denosumab, ask your prescriber or pharmacist specifically about available biosimilar options. If your insurer’s formulary includes an interchangeable denosumab biosimilar like Jubbonti, your pharmacist may be able to substitute automatically. For non-interchangeable biosimilars like PONLIMSI, a prescriber action is required. Medicare Part B, through which administered biologics are often covered, has specific biosimilar substitution rules worth understanding with your provider.

If you are on Xolair for allergic asthma, nasal polyps, urticaria, or food allergy

A biosimilar is not yet available. Teva’s application is under review, and even after approval, launch timing will depend on regulatory processes and commercial decisions. Continue your current treatment as prescribed. Monitor your insurer’s formulary for updates in 2026 and 2027.

The Gap Between Biosimilar Approval and Patient Savings

The denosumab biosimilar story is instructive for understanding how U.S. drug pricing actually works and why regulatory approval of a biosimilar does not automatically translate to patient savings.

When Prolia’s key patents began expiring, the expectation was that biosimilar competition would drive meaningful price reductions, as it has in Europe. Instead, 19 FDA approvals later, the most aggressive biosimilar discount achieved is about 14.5% below Prolia’s list price. The originator still commands most of the market. The structural reasons are complex: Amgen’s rebate practices, the lack of interchangeability designation for most competitors, the physician-administered nature of the injection (which keeps it under Part B rather than Part D, with different substitution rules), and the clinical hesitancy around switching patients who have been stable on a therapy that must not be interrupted without a plan.

Flanigan et al. noted in their 2025 Journal of Medical Economics budget impact analysis that even a small discount of 5% for a biosimilar referencing Xgeva and Prolia could represent millions of dollars in savings for a health plan, with the potential for reinvestment to further expand access. Those savings are real at scale even when they feel modest at the individual patient level.

None of this means biosimilar approvals like PONLIMSI are without value. For payers, even modest per-dose discounts multiply across large patient populations. For patients in countries with less fragmented pricing structures, competitive biosimilar availability is genuinely transformative. And building a competitive biosimilar market, however slowly, creates the foundation for the price competition that patients deserve.

The omalizumab filing, if it leads to approval and launch, enters a somewhat less saturated biosimilar market. The recent addition of the food allergy indication has expanded the potential patient population substantially. That approval, if and when it comes, may be a more commercially differentiated moment than PONLIMSI in the already crowded denosumab space.

For related coverage of how access and affordability are shaping the drug landscape in 2026, see our post on FDA approval of the first generic dapagliflozin, where a similar story of high list prices, biosimilar or generic entry, and the gap between approval and real-world savings is unfolding in the type 2 diabetes space.

Sources

Teva press release: Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair (omalizumab). March 30, 2026. ir.tevapharm.com.

Clinical Advisor coverage: FDA Approves Teva’s Prolia Biosimilar Ponlimsi, Accepts Xolair Biosimilar for Review. clinicaladvisor.com. April 2026.

Drug Topics: FDA Approves Denosumab-Adet as Biosimilar to Prolia. drugtopics.com. March 2026.

Center for Biosimilars: FDA Approves Teva Biosimilar for Denosumab in Osteoporosis. centerforbiosimilars.com. March 2026.

GaBI Online: FDA approves denosumab biosimilar Ponlimsi. gabionline.net. April 2026.

Medscape: Two More Denosumab Biosimilars Approved in the US. medscape.com. October 2025.

Managed Healthcare Executive: Biosimilar denosumab could save $0.59 per member per month. managedhealthcareexecutive.com. February 2026.

Journal of Medical Economics budget impact: Flanigan J, Chaplin S, et al. A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population. J Med Econ. 2025;28(1):2027-2038. doi:10.1080/13696998.2025.2027-2038.

PONLIMSI Phase 3 trial: NCT04729621. ClinicalTrials.gov.

GoodRx pricing: How Much Is Prolia Without Insurance? goodrx.com.

Rebound fracture risk: Rebound vertebral fractures after denosumab discontinuation. PMC6683162.

Denosumab mechanism: Denosumab. StatPearls. NCBI.

RANKL biology: RANKL in bone biology. PMC3386061.

Hip fracture mortality: Hip fracture 1-year mortality. PMC6530614.

FDA biosimilars explained: Biosimilar and Interchangeable Products. FDA.gov.

FDA approved biosimilar products: FDA-Approved Biosimilar Products. FDA.gov.

Prolia FDA approval: FDA approves denosumab for osteoporosis. FDA.gov.

Xgeva FDA approval: FDA approves denosumab (Xgeva). FDA.gov.

Xolair FDA approval: FDA approves omalizumab for allergic asthma. FDA.gov.

IgE biology: IgE in allergy. StatPearls. NCBI.

PBM market structure: Pharmacy Benefit Managers. PMC7748166.

Bisphosphonates: Bisphosphonates. StatPearls. NCBI.

Patient resources: Bone Health and Osteoporosis Foundation | FDA Biosimilar Products List | GoodRx Prolia pricing

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about denosumab therapy, including switching between reference products and biosimilars, should be made in consultation with a qualified prescriber familiar with the patient’s bone health history and fracture risk. Never discontinue denosumab without medical guidance.

April 4, 2026